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1 Introduction 
The application of microarrays for expression profiling was first published in 1995.1 
Since this time, the number of publications related to microarrays increased 
exponentially (figure 1). This demonstrates the rapidly increasing impact of this 
technology on toxicological research2, genetic diagnostics3, drug discovery4 and basic 
research applications.5-8 DNA-microarrays are a large-scale and high-throughput 
technology to obtain information on relative abundances of up to many thousands of 
transcripts from a single biological sample simultaneously. This allows studying the 
complex interplay of all the genes in a cell. The global patterns of gene activities 
become observable with few microarray experiments. These expression patterns may 
provide clues to regulation and possible functions of previously uncharacterized genes 
or genes known in a different context. The combination with metabolic schematics can 
help to understand how pathways interact and change under varying conditions. 
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Figure 1. Number of publications about DNA-microarrays from 1995-2004. The given numbers 
are the amount of references found in PubMed 9 searching for publications related to 
microarrays. 
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1.1 DNA-Microarray Technology  
Although there are many different kinds of DNA-microarrays available, the basic 
technology is for all types the same. DNA fragments with sequences unique for the 
genes or transcripts of interest are generated and immobilized at defined positions 
(spots or features) on a solid surface (matrix). Labelled nucleic acids from the samples 
are prepared and allowed to hybridize to the complementary probes spotted on the 
matrix. The amounts of hybridized samples are read out for each spot by appropriate 
imaging techniques, depending on the kind of label used. Changes in gene expression 
between two samples are determined by the difference in the intensities of the 
corresponding spots. When fluorescent labels are used, the two samples to be 
compared can be labelled with different colors (fluorophores) and hybridized to the 
same microarray. In this case, each spot contains the information of the abundance of 
one particular gene or transcript in both of the samples. Figure 2 shows the schematic 
of the whole process for the example of a competitive hybridization of two fluorescently 
labelled samples. 
For the matrix, materials like nylon membrane, plastic or modified glass surfaces can 
be applied. The original membrane used for nucleic acid immobilization was 
nitrocellulose, selected by E. M. Southern for his Southern blotting method.10 Recently, 
nylon has been promoted as a substrate for nucleic acid binding owing to its greater 
physical strength and binding capacity, and a wider range of available surface 
chemistries was offered for optimizing nucleic acid attachment. Immobilization on nylon 
membranes can be performed via physical adsorption, UV cross-linking, or chemical 
activation. Immobilization on nylon has been demonstrated to be more durable during 
repeated probe stripping than immobilization on nitrocellulose.11 Nylon membranes 
have also been used in methods to detect DNA by colorimetry, fluorometry, and 
chemiluminescence.12 The high background typically observed with nylon membranes 
is their principal disadvantage. This may be due to a nonspecific binding of the sample 
or detection system, or to some natural property of the membrane. Nitrocellulose has a 
lower binding capacity and is weaker than nylon, but it has far lower background for 
most detection systems. Traditional membranes such as nylon and nitrocellulose have 
been used in the production of macroarrays, but their use in microarrays is limited 
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because of the low spot resolution. Because these membranes exhibit lateral wicking 
characteristics, the label tends to spread from the point of application. This has been a 
limitation in the production of high-density arrays. 
Figure 2. Schematic of microarray technology. A PCR product from a DNA clone is purified and 
spotted on a glass surface with the help of robotic printing. RNA is extracted from two different 
samples and converted into fluorescently labelled cDNA. The labelled cDNAs of the two 
samples are then mixed and hybridized to the array. The array is finally scanned to get the 
relative fluorescence intensities for each spot. Picture taken from http://www.bioteach.ubc.ca/ 
MolecularBiology/microarray. 
Modified glass surfaces (epoxy-, aminosilan, or poly-L-lysine coated) are the most 
commonly used matrices for high-density microarrays. Similar to the application on 
membranes, the probes can be mechanically spotted on the surface and subsequently 
be immobilized by UV-crosslinking or baking. Figure 3 show a spotting robot for glass 
arrays and a print-tip head in action. 
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Figure 3. Microarray spotting robot (left) and detail View of a Print-Tip Head (right). The left 
pictures was taken from http://www.dkfz-heidelberg.de/kompl_genome/, the right picture was 
taken from http://arrayit.com/Products/ Printing/Stealth/stealth.html. 
The Affymetrix Company holds the patent on a robust method to synthesize short 
oligonucleotides (25mers) directly on the glass surface with a combination of 
photolithography and combinatorial chemistry.13-14 This system is named GeneChip™ 
technology. Another unique feature of Affymetrix GeneChip™ arrays is the probe 
design: the sequences of the transcripts of interest are addressed by a set (5-20) of 
different 25mer oligonucleotides. To be able to correct for cross-hybridization of the 
samples with the relatively short probes, each probe set is complemented by a set of 
similar probes containing a base substitution in the middle of the probe sequence 
causing a mismatch to the target sequence. The difference of the hybridization signals 
on corresponding “perfect-match” and “mis-match” spots is finally used to estimate the 
relative abundance of the sequence of interest. In consequence, the short probes can 
discriminate well between single nucleotide polymorphisms.15-16 Affymetrix does not 
promote competitive hybridizations of fluorescently labelled samples. Instead, the 
samples are labelled with biotin. The hybridization signal is generated by a 
streptavidin-phycoerythrin conjugate. Streptavidin binds to the biotin moieties of the 
hybridized samples. The signal is amplified on the chip by the application of goat-
antibodies against streptavidin and biotinylated anti-goat antibodies that in turn bind 
multiple further streptavidin-phycoerythrin conjugates. 
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Most other microarray techniques make use of fluorescent labelling, whether used for 
single-color or for dual-color (competitive) hybridizations. The fluorophors can either be 
incorporated directly during the synthesis of the cDNA or during an in-vitro transcription 
adding already labelled nucleotides to the reaction mixture, or indirectly by adding 
amino-allylated nucleotides that are subsequently coupled with free monoreactive 
fluorophors.  
1.2 Pulmonary Hypertension  
Pulmonary Hypertension (PH) is clinically defined as a mean pulmonary arterial 
pressure (PAP) of more than 25 mm Hg at rest and 30 mm Hg during exercise while 
the normal mean pulmonary artery pressure in adults is 12-16 mm Hg.17 PH is a life 
threatening disease that leads without treatment after 28 month in mean to right heart 
insufficiency and death, histologically characterized by lumen-obliterating endothelial 
cell proliferation and vascular smooth muscle hypertrophy of the small precapillary 
pulmonary arteries.18  
1.2.1 Historical Background 
The disease was first described over 100 years ago in a patient with right heart failure 
whose necrosis showed no obvious reason for pulmonary arteriosclerosis.19 In 1901, 
Ayerza noted the profound cyanosis associated with this disorder, and described the 
disorder as cardiacos negros but the term so-called pulmonary hypertension was 
coined by Dresdale and his colleagues in 1951.20 In 1954, Dresdale et al. reported the 
first documented cases of familial primary pulmonary hypertension (PPH).21 In 1967, an 
increased frequency of PPH in Europe was linked to the use of the appetite 
suppressant aminorex fumarate. As a result, in 1973 WHO convened an international 
meeting on PPH.  
The frequency of PPH in the general population is estimated at 1-2 cases per million 
people. PPH can develop at any age; the mean age at diagnosis is 36 years.22 PPH 
began surfacing through the 1970s because of the latency period found to exist 
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between drug use and PPH diagnosis of 4-6 years. Today familial and sporadic cases 
of PPH are continuously diagnosed. A delay in diagnosis results in the disease 
progressing to late stages without proper treatment.  
There is a female excess of PPH in both adult disease (ratio women/men 1.7-3.5) and 
childhood familial PPH.23 More recently, in the United States and France, several cases 
of PPH have been associated with the appetite suppressants, fenfluramine and 
dexfenfluramine. In the United States it has been estimated that 300 new cases of PPH 
are diagnosed each year. Apparently it also affects people of all racial and ethnic origin 
equally. Apart from the primary pulmonary hypertension there are several reasons for 
the manifestation of increased pulmonary pressure secondarily and in the context of 
other diseases and states. Examples are the thrombembolic disease, veno-occlusive 
disease or chronic hypoxia. 
1.2.1.1 Classification 
There are many causes and, hence, ways of classifying the pulmonary hypertension.24 
Originally, PH was classified as either primary (idiopathic) or secondary (associated 
with diverse cardiopulmonary and systemic diseases). However, following a World 
Health Organization symposium held in Evian, France in 1998, a revised classification 
for PH was adopted. This classification separated conditions that directly affect the 
pulmonary arterial tree from disorders that either predominantly affects the venous 
circulation or conditions that affect the pulmonary circulation by altering respiratory 
structure or function. Thus, while the term secondary pulmonary hypertension was 
abandoned, PPH remained the term of choice to define familial or sporadic disease of 
undetermined cause. In addition, the Evian meeting emphasized the role of functional 
assessment of patients with PH, and a functional assessment classification, modified 
from the New York Heart Association functional classification, was also adopted. The 
impact of these classifications is perhaps best reflected by the regulatory approval of 
several new drugs for PAH, recognizing the common features shared by patients with 
this disease processes.25 
Shortcomings in the Evian classification, however, became clear with its application in 
the clinical setting, coupled with further developments in the elucidation of the 
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pathogenesis of PH. A revision of this classification was proposed at the third World 
conference on pulmonary hypertension, held in Venice in 2003: PPH has been 
replaced by idiopathic PAH (IPAH) or, when supported by genetic investigation, familial 
PAH (FPAH). The experts believed that these terms more accurately and appropriately 
describe our contemporary understanding and clinical perspective.25 
1.2.1.2 Histopathology 
Chronic PH is associated with structural changes in both the pulmonary vasculature 
and the right ventricle (figure 4). Pathological findings consistent with IPAH/FPAH were 
first described in autopsy specimens a century ago.26 The pulmonary arteries are 
characterized by intimal fibrosis, medial hypertrophy, adventitial proliferation, 
obliteration of small arteries and on occasion, vasculitis or changes in the walls of the 
pulmonary veins.27 A fascinating focal vascular structure, the plexiform lesion, is found 
in many cases of IPAH/FPAH. Plexiform lesions are not pathognomonic for 
IPAH/FPAH, because they are also found in cases of severe PAH associated with 
other diseases. The plexiform lesion resembles the renal glomerulus, and its many 
channels are lined with endothelial cells rich in type 3-nitric oxide (NO) synthase, factor 
VIII, vimentin, and the receptor for vascular endothelial growth factor.27 In the central 
core of the lesion, the endothelial cells are cyclin-kinase inhibitor p27/kip1–negative 
cells, whereas in peripheral areas adjacent to sites of angiogenesis, p27/kip1–positive 
cells are present.28 It has been proposed that plexiform lesions are a form of neoplastic 
lesion, reflecting a dysregulation of endothelial growth.29 Alternatively, plexiform lesions 
may represent an angiogenic response to local ischemia or hypoxia, as occurs with the 
creation of collateral vessels associated with obstructed arteries in other vascular beds. 
Computerized 3D reconstructions of vessels in IPAH/FPAH demonstrate that plexigenic 
lesions occur distal to vascular obstructive lesions.28 
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Figure 4. Photomicrography of lung section. (A) Control shows a normal small pulmonary artery 
with typically thin muscular wall, (B) shows a small pulmonary artery with hyperplasia of smooth 
muscle cells and thickening of the wall during PPH, (C) Shows fibrous intima proliferates on 
inner wall of small pulmonary artery, and (D) concentric laminar intima fibrosis with bands of 
scarred tissue build up on inner wall, substantially narrowing the blood vessel. (Picture adopted 
from http://www.healthnewsflash.com/conditions/primary_pulmonary_hyper-tension.php#pr). 
1.2.2 Causes for Primary Pulmonary Hypertension 
In a recent important advance, a genetic cause of the familial form of primary 
pulmonary hypertension has been discovered. Mutations in bone morphogenetic 
protein receptor 2 (BMPR2) have been associated with familial PAH and sporadic 
PPH.30 BMPR2 is a cell signalling protein that plays a role in lung development, and the 
mutations found in patients with PPH are believed to reduce signalling in the BMP 
pathway. This, in turn, could lead to the over-proliferation of cells (figure 5). 
(A) 
(C) 
(B) 
(D) 
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Figure 5. BMP signalling pathway. Picture adopted from Strange JW. et al.31 
In pulmonary arterioles, the over-proliferation of smooth muscle cells is the 
characteristic of PPH, leading to progressive muscularization of normally non-muscular 
parts of the blood vessels, thereby allowing these newly musculated parts to 
vasoconstrict. This increased vasoconstriction finally leads to hypertension. It is not 
clear whether familial PAH is molecularly distinct from sporadic/idiopathic PAH. 
Sporadic cases of PAH are more common than familial cases, and their development 
can be associated with several things including: pregnancy, hypothyroidism, and the 
use of oral contraceptives, cocaine, or the appetite suppressant drugs, phentermine-
fenfluramine (phen-fen) and monocrotaline extracts. People with autoimmune disease 
or late stage of HIV infection can also develop PAH.  
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1.2.3 Animal Models 
Application of some toxins to the animal’s lung causes inflammatory responses. In 
consequence of the cell injuries and the inflammatory processes, the animals develop 
acute or chronic PH. The best-characterized animal models for PH comprise rats 
treated with the alkaloid monocrotaline. Additionally, mice treated with pneumolysin, a 
pore-forming exotoxin of Stretococcus pneumoniae, developed PH as well. Further, 
chronic forms of PH can be induced by a low environmental oxygen tension. 
1.2.3.1 Hypoxia-based Model  
Exposure of mice to low levels of environmental oxygen results in alveolar hypoxia and 
reliably causes chronic pulmonary hypertension and morphological alterations of the 
precapillary pulmonary vessels. Chronic hypoxia can be induced by exposing cattles 32 
or several mammalian species to normal air at hypobaric pressures or to oxygen-poor 
air (10 %) at normal pressure. Chronic hypoxic exposure of animals has been used for 
decades to induce pulmonary vascular remodelling. 
1.2.3.2 Monocrotaline (MCT) Based Model 
Monocrotaline is a pyrrolizidine alkaloid toxin from Crotalaria spetabilis.33 It is 
hepatotoxic, pneumotoxic, and causes chronic pulmonary hypertension in humans and 
animals.34 People are exposed to pyrrolizidine alkaloid as through consumption of 
herbal medicines made from pyrrolizidine alkaloid-containing plants or by ingesting 
food grains contaminated with seeds or other components of pyrrolizidine alkaloid-
containing plants.33  
MCT is bioactivated in the liver by cytochrome P450 monooxygenases to pyrrolic 
metabolites, which travel via the circulation to the lungs, where they cause injury by 
unknown mechanisms.35 One putative metabolite of MCT is monocrotaline pyrrole 
(dehydromonocrotaline), a moderately reactive, bifunctional alkylating agent that 
produces sinusoidal endothelial cell injury, hemorrhage, fibrin deposition, and 
coagulative hepatic parenchymal cell oncosis in centrilobular regions of the liver.  
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In the rat model, systemically applied MCT induces endothelial inflammation with a 
structural remodelling of the lung arteries leading to pulmonary hypertension and 
similar histological changes like PAH in humans. The inflammatory mechanisms 
appear to play a significant role in some types of PH, including human types of PH.36 
The MCT rat model has become one of the most widely used animal models to study 
various aspects of PH.33 Rats exposed to MCT develop an acute pulmonary vascular 
inflammatory reaction with subsequent remodelling including pulmonary artery smooth 
muscle hypertrophy, leading to a persistent severe pulmonary hypertension after 3 to 4 
weeks.37-39 This is a reproducible and well-established model of the disease which may 
be of value for investigating some aspects of this condition.40 For instance, pulmonary 
vascular inflammation seems to play a key role in subjects developing pulmonary 
arterial hypertension in the context of toxic oil syndrome, autoimmune diseases, or 
infectious conditions.41 Pulmonary vascular inflammation may also play a key role in a 
subset of patients with idiopathic pulmonary hypertension. However, the development 
of the medial hypertrophy revealed that it is preceded by intense metabolic activity and 
proliferation of the pulmonary endothelial cell layer.41  
In the normal pulmonary circulation, a balance favouring vasodilation and inhibiting 
proliferation is maintained between the vasodilators like prostacyclin and nitric oxide on 
the one hand, and potent pulmonary vasoconstrictors like endothelin I on the other 
hand. In PAH, imbalances of vasodilator and vasoconstrictor agents have been 
implicated in both the predominance of increased vasomotor tone and the chronic 
remodelling of resistance vessels, including vascular smooth muscle cell growth. The 
balance is tilted toward the production of endothelin-I and an enhanced excretion of 
thromboxane metabolites has been noted.42 Additionally, a reduced excretion of 
prostaglandin can be detected in the circulating blood. Moreover, enhanced activities of 
phosphodiesterases (PDEs), which hydrolyze the prostaglandin- and NO-induced 
second messengers, cAMP and cGMP, were observed in experimental conditions of 
pulmonary hypertension.43 
Among the large variety of cellular functions that are orchestrated by the cAMP-
dependent protein kinase A cascade, the anti-inflammatory effects caused by 
increased cAMP levels have attracted considerable interest both in immunological and 
pharmacological research. Intracellular cAMP concentrations increase as a 
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consequence of receptor-triggered adenylyl cyclase activation or by decreased activity 
of phosphodiesterases, which regulate the hydrolysis of cAMP and cGMP (figure 6). 
 
Figure 6. Cyclic nucleotides as second messengers in the regulation of the vascular tone. 
cAMP is an important second messenger regulating diverse function such as cell shape, protein 
phosphorylation, gene transcription, etc. As much as 10 subtypes of adenylyl cyclase are 
capable of converting ATP to cAMP. Hydrolysis of cAMP is mediated through a class of 
enzymes known as PDEs. These enzymes can be classified according to their specificity for 
cAMP and cGMP. There exist PDEs that only hydrolyze cAMP or cGMP, as well other subtypes 
that hydrolyze both cyclic nucleotide and therefore limit their action. + = Stimulation; – = 
inhibition (Picture adopted from Uder, M. et al.). 44  
The family of mammalian phosphodiesterases consists of at least 11 isoenzymes. 
Some PDEs (PDE3, PDE4 and PDE5) seem to play a role in smooth muscle 
relaxation.45 In inflammatory cells, including mast cells, eosinophils, macrophages, T-
lymphocytes and structural cells, PDE3, 4, and 5 are predominant.46 Due to higher 
PDE3 and PDE4 concentrations in the cells, PDE3/4 inhibitors that had been proven 
safe were targeted as possible options for PH and asthma treatment. When PDEs are 
inhibited, the cellular level of cAMP increases, resulting in smooth muscle relaxation 
and potentiation of the bronchodilator effect of agonists. Tolafentrine, which is a 
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synthetic PDE 3/4 inhibitor, possesses a strong antiproliferative effects in the 
pulmonary circulation47. The reduction in the number of peripheral arteries in MCT-
treated animals reflects endothelial injury and occlusion of peripheral vessels. 
Tolafentrine reduces the wall thickening and remodelling of intrapulmonal arteries. 
Moreover, a significant increase in vascularization by tolafentrine may result from 
vascular endothelial growth factor, which is known to be induced by cAMP-increasing 
agents.48  
1.2.3.3 Pneumolysin (PLY) Model 
Streptococcus pneumoniae, a gram-positive bacterium, is the most prevalent pathogen 
involved in community-acquired pneumonia49, septic meningitis50, and otitis media.51 In 
the pre-antibiotic era streptococcal pneumonia or pneumococcal pneumonia had a high 
fatality rate, being a frequent cause of death in the elderly.  
Invasive pneumococcal disease appears to depend on both pneumococcal cell wall 
components including peptidoglycan and lipoteichoic acid, as well as a multitude of 
virulence factors.52-53 A number of pneumococcal proteins have been characterized as 
putative virulence factors, among them pneumolysin (PLY), the neuraminidases A and 
B, and hyaluronidase54 that appear to be involved in the pathogenesis of meningitis and 
other related diseases. Pneumolysin is involved in inflammatory processes, activating 
neutrophils/macrophages and the complement system.55 This effect may participate in 
the pathogenesis of septic organ failure and the host response may critically depend 
on the compartmentalization and amount of toxin release.  
PLY is a cytoplasmic 53-kDa protein that belongs to a group of thiol-activated 
cholesterol-dependent cytolysins and interacts with its cholesterol receptor on target 
cells, leading to pneumolysin insertion into target-cell membranes and subsequently to 
pore formation and cell lyses.56 PLY differs from others in this family because it lacks 
the N-terminal signal sequence that would facilitate its transport out of the cytoplasm. 
Instead, it is thought that the toxin is released from the pneumococcal cytoplasm via 
the enzyme autolysin LytA, which induces cell wall degradation and the release of 
cytoplasmic contents. The crystal structure of one member of the family, perfringolysin 
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has been solved by X-ray crystallography, by the group of Mike Parker in Melbourne 
(figure 7). 
Domain 1
Domain 2Domain 3
Domain 4
TRP rich motif
 
Figure 7. Protein Structure of Perfringolysin. It contains of 4 distinct domains indicated by 
different colors. These domains involved for cell binding, oligomerization, and pore formation 
processes. (Picture taken from Jamie Rossjohn et al.). 57 
By pore-formation PLY has the capacity to damage the extracellular matrix or the 
plasma membrane of eukaryotic cells. The damage not only may result in the direct 
lysis of cells but also can facilitate bacterial spread through tissues. Toxins that 
mediate this cellular damage do so by either enzymatic hydrolysis or pore formation. 
The concept of membrane damage as an effector mechanism of bacterial exotoxins 
arose during the 1970s through the work on α-toxin by Freer et al. 1968 and, 
subsequently, Thelestam and Molby (1975). These studies generated the idea that 
staphylococcal α-toxin produced permeability defect in membranes. The α-toxin is 
cytolytic to a variety of cell types, including human monocytes, lymphocytes, 
erythrocytes, platelets, and endothelial cells.58  
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The molecular mechanism of the damage of cellular membranes by the α-toxin 
comprises several sequential events (figure 8). When S. pneumoniae cells burst, 
pneumolysin is released and binds to cholesterol in cell membranes by either 
unidentified high-affinity receptors or through nonspecific absorption to substances 
such as phosphotidylcholine or cholesterol on the lipid bilayer.58 Second, membrane-
bound protomers oligomerize and form arc and ring structures (pores). Third, the 
heptamer undergoes a series of conformational changes that create the stem domain 
of the toxin, which is then inserted into the membrane.  
The α-toxin pore allows the influx and efflux of small molecules and ions that eventually 
lead to swelling and death of nucleated cells. Moreover, pore formation has also been 
shown to trigger secondary events include endonuclease activation, increased platelet 
exocytosis, release of cytokines and inflammatory mediators, and production of 
eicosanoids.58 
 
1. lateral diffusion
2. oligomerization
3. insertion 3. pore-formation 
K+ 
Ca++
NO-synthasephospholipase
prostaglandine
thromboxan 
NO
 
Figure 8. Schematic of the mechanism of pore formation by pneumolysin. The toxin is secreted 
as a monomer (left) and incorporated in the cell membrane of its target cells. The 
transmembrane pores are formed in the membrane after ologomerization. The pores are 
permissible for different ions. The pore-induced ion fluxes activate target cells most likely by an 
increased intracellular Ca++ concentration, stimulating for example the production of nitric oxide 
or leukotrienes. 
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2 Aim of this Work 
This thesis consists of two parts.  
The first part focuses on establishing a reliable platform for microarray experiments. It 
shows the comparison of different protocols for sample preparation, sample labelling 
and competitive hybridization on cDNA- and oligonucleotide-spotted microarrays. 
Various methods and important parameters are optimized, in particular RNA extraction, 
RNA preamplification, direct and indirect labelling, and slide processing (preproces-
sing, hybridization, and washing). Particular importance is addressed to the compa-
rison of different preamplification protocols that allow the use of trace amounts of 
sample material for microarray analyses. 
The second part shows the application of different array technologies for gene 
expression profiling to two important models of pulmonary hypertension. Affymetrix 
GeneChips™ are utilized to reveal characteristic changes in gene expression patterns 
of pneumolysin-induced pulmonary hypertension in mice, whereas cDNA-macroarrays 
and oligonucleotide-spotted microarrays were used to study the gene expression in 
monocrotaline-induced and tolafentrine-attenuted pulmonary hypertension in rats. 
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3 Materials 
3.1 Animals  
Male Sprague-Dawley rats (Charles River, Sulzfeld, Germany) 
Female BALB/c mice (Charles River, Sulzfeld, Germany) 
3.2 DNA Microarrays 
Expression arrays were used for expression profiling of rat and mouse samples. The 
arrays were spotted with either cDNAs (“cDNA”) or with gene-specific 
oligodeoxynucleotides (“oligo”). 
Table 1. Expression arrays. 
Organism Matrix Probes Number of Spots Name Supplier 
rattus 
norwegicus 
nylon cDNA 1176 Atlas Rat 1.2 BD Siosciences, 
Heidelberg, Germany 
mus 
musculus 
glass cDNA 20000 
2 x spotted 
Mouse 20K, 
Lion 
DKFZ, Heidelberg, 
Germany 
mus 
musculus 
glass oligo 
(50mer) 
10000 Mouse 10K MWG-Biotech, Ebersberg, 
Germany 
mus 
musculus 
glass oligo 
(60mer) 
22000 Mouse 22K Agilent Technologies, 
Waldbronn, Germany 
mus 
musculus 
glass oligo 
(25mer) 
36000 MG U74A09 Affymetrix, Santa Clara, 
CA, USA 
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3.3 Instruments 
Table 2. Instruments. 
Instrument Supplier 
GeneTAC Hybridization station PerkinElmer, Applied Biosystems, Foster City, USA 
GenePix 4100A scanner Axon Instruments, Union City, CA, USA 
Bioanalyzer 2100 Agilent Technologies, Waldbronn, Germany 
ND-1000 UV spectrophotometer NanoDrop, Montchanin, USA 
ABI 7700 Sequence Detector PerkinElmer, Applied Biosystems, Foster City, USA 
Icycler Bio-Rad, Munich, Germany 
Touch Down hot Lid PCR cyler 
TRIO Thermoblock 
Hybaid, Heidelberg, Germany 
Biometra, Göttingen, Germany 
Liquid scintillization counter Hidex, Turku, Finnland 
Typhoon phsphoimager system Amersham Biosciences, Freiburg, Germany 
 
3.4 Chemicals and Biochemicals 
Table 3. Chemicals and Biochemicals. 
Chemical Supplier 
PeqGOLDTM TriFast solution peqlab, Erlangen, Germany 
GiTC (4M 25mM Na-3-citrate: 0.5% 
laurylsarcosin, 100mM Tris/Hcl) 
Sigma, Taufkirchen, Germany 
β-mercaptoethanol (98%) Sigma, Taufkirchen, Germany 
Phenol saturated with 0.1 M citrate Buffer, pH 
4.3 +/- 0.2  
Sigma, Taufkirchen, Germany 
CHCl3 (99%) Sigma, Taufkirchen, Germany 
C3H8O(99%) Sigma, Taufkirchen, Germany 
NaOAc (2M, pH 4.5) Sigma, Taufkirchen, Germany 
100% ethanol  Sigma, Taufkirchen, Germany 
NaOH (1M) Merck,Darmstadt, Germany 
HCl (1M) Merck,Darmstadt, Germany  
TE (pH 7.5) Sigma, Taufkirchen, Germany 
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MCT (20 mg/ml) Sigma, Deishofen, Germany 
100% ethanol  Merk, Darmstadt, Germany 
Agrose (TopvisionTM) MBI Fermentas, Walldorf Baden, Germany 
Ethidium Bromide (10 mg/ml) Carl Roth, Karlsruhe, Germany 
dATP, dCTP, dGTP and dTTP, (100 mM) Amersham Biosciences, Freiburg, Germany 
Cy5 dCTP (1mM) Amersham Biosciences, Freiburg, Germany 
Cy3 dCTP (1mM) Amersham Biosciences, Freiburg, Germany 
Cy3 monofunctional reactive dye Amersham Biosciences, Freiburg, Germany 
Cy5 monofunctional reactive dye  Amersham Biosciences, Freiburg, Germany 
Cy3 UTP (1mM) PerkinElmer, Boston, USA 
Cy5 UTP (1mM) PerkinElmer, Boston, USA 
Biotin-11 CTP  PerkinElmer, Boston, USA 
Biotin-16 UTP  
MgCl2 (25 mmol/L) 
10X PCR buffer  
PerkinElmer, Boston, USA 
PerkinElmer, Weiterstadt, Germany 
PerkinElmer, Weiterstadt, Germany 
Salmon Sperm DNA  Sigma, Taufkirchen, Germany 
Bovine Serum Albumin (50 mg/ml) Invitrogen, Karlsruhe, Germany 
ULTRAhybTM buffer  Ambion, Dresden, Germany 
SDS 99% Sigma 
NaCl Sigma 
EDTA Sigma 
Boric acid Merk 
α-32 P-dATP Amersham Biosciences, Freiburg, Germany 
 
3.5 Buffers and Solutions  
1 M Tris-HCl stock 
Tris or TRIZMA base - 60.55 g  
Milli-Q water - 400 ml 
The pH was adjusted with conc. HCl to 7.5.  
Volume was adjusted to 500 ml with Milli-Q water. 
0.5 M EDTA stock 
EDTA - 93.05 g 
Milli-Q water - 400 ml 
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The pH was adjusted with NaOH pellets to 7.5.  
Volume was adjusted to 500 ml with Milli-Q water. 
1 M Sodium citrate stock 
Sodium citrate - 29.4 g  
Volume was adjusted to 100 ml with Milli-Q water. 
4M GTC  
GTC - 47.3 g 
25 mM Sodium citrate - 2.5 ml from 1 M stock 
0.5% N-lauroyl sarcosine - 0.5 g 
100 mM Tris - 1.21 g 
Volume was adjusted to 100 ml with RNase-free water. 
2M NaOAc 
Sodium acetate - 54.4 g  
Volume was adjusted to 100 ml with Milli-Q water. 
The pH was adjusted with 100% acetic acid (Merk) to 4.5. 
TE (10 mM Tris, 1.0 mM EDTA, pH7.5) 
Tris- stock (1M, pH 7.5) - 1 ml 
EDTA-stock (0.5M, pH 7.5) - 200 µl 
Volume was adjusted to 100 ml with Milli-Q water. 
Saline citrate buffer (SSC) 20X 
NaCl - 175 g  
Sodium citrate - 88 g 
Milli-Q water - 900 ml 
pH was adjusted to 7.0 with HCl and volume was and adjusted to 1 liter. 
10% SDS 
SDS – 10 g 
Volume was adjusted to 100 ml with distilled water. 
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3.6 Oligodeoxynucleotides  
Random hexamers (50µM) were obtained from Applied Biosystems, Darmstadt, 
Germany, Oligo-dT primer (12-18 nt, 0.5µg/µl) were bought from Eurogentec, Searing, 
Belgium. Primers were ordered from MWG, Ebersberg, Germany. 
Table 4. Primers. 
Targe gene 1 Genbank 
Accs.No. 
Sequence 
5’→3’ 
Length 
(nt) 
Amplicon 
Length 
(bp) 
mGAPDH-FP NM_ 
001001303 
GTGATGGGTGTGAACCACGAG 21 121 
mGAPDH-RP  CCAACAATGCCAAAGTTGTCA 21  
mGAPDH-TM-
Probe 
 GTGCAGGATGCATTGCTGACAATCTTGA 28  
rPBGD-FP BC088162 ATGTCCGGTAACGGCGGC 18 139 
rPBGD-RP  GGTACAAGGTTTTCAGCATTCG 22  
rPBGD-TM-
Probe 
 CCAGCTGACTCTTCCGGGTGC 
CCAC 
25  
mGAPDH-e-
3’UTR-FP 
NM_ 
001001303 
ACAGGGTGGTGGACCTCATG 20 102 
mGAPDH -e-
3’UTR-RP 
 GTTGGGATAGGGCCTCTCTTG 21  
1 the first letter indicates the organism: r = rattus norwegicus, and m = mus musculus.  
3.7 Enzymes  
Table 5. Enzymes. 
Chemical Supplier 
CyScribe reverse transcriptase (100U/µl) Amersham Biosciences, Freiburg, Germany 
DNase Set (50) (1500U) Qiagen, Hilden, Germany 
DNA polymerase I (10U/µl) Invitrogen, Karlsruhe, Germany 
RNase Inhibitor (20 U/µl) Applied Biosystems, Darmstadt, Germany 
MuLV Reverse Transcriptase 50 U/µl Applied Biosystems, Darmstadt, Germany 
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M-MLV Reverse Transcriptase, RNase H 
Minus, Point Mutant (200 U/µl) 
Promega, Madison, USA 
SuperScript™ II RNase H⎯ Reverse 
Transcriptase, 200U/µl, first and second 
strand buffers 
Invitrogen, Karlsruhe, Germany 
RNAseout, 40 U/µl Invitrogen, Karlsruhe, Germany 
E.coli DNA ligase, 10 U/µl Invitrogen, Karlsruhe, Germany 
E.coli DNA Polymerase I, 10 U/µl Invitrogen, Karlsruhe, Germany 
RNAse H, 2 U/µl Invitrogen, Karlsruhe, Germany 
Proteinase K, 10 mg/ml Sigma-Aldrich, Taufkirchen, Germany 
T4-DNA Polymerase, 5 U/µl Invitrogen, Karlsruhe, Germany 
RNAse, DNAse free, 20 mg/ml Invitrogen, Karlsruhe, Germany 
Klenow Polymerase, 2 U/µl Roche diagonstics, Mannheim, Germany 
Taq DNA-Polymerase, 5 U/µl Applied Biosystems, Brunnenweg, Germany 
3.8 Kits  
Table 6. Kits. 
Chemical Supplier 
RNeasy Mini Qiagen, Hilden, Germany 
Oligotex mRNA Mini Qiagen, Hilden, Germany 
SMART Fluorescent Probe Amplification BD Biosciences, Heidelberg, Germany 
RiboAmp® RNA Amplification Arcturus, Mörfelden-Walldorf, Germany 
RiboMax T7 Promega, Mannheim, Germany 
CyScribe First Strand cDNA Labelling Amersham Biosciences, Freiburg, Germany 
Fluoroscript labelling Invitrogen, Karlsruhe, Germany 
Ominiscript® RT Qiagen, Hilden, Germany 
Microcon columns YM-30 and YM-50 Millipore, Schwalbach, Germany 
QIAquick PCR Purification Qiagen, Hilden, Germany 
RNA 6000 Nano Chips Agilent Technologies, Waldbronn, Germany 
qPCRTM Mastermix Eurogentec, Seraing, Belgium 
qPCRTM Mastermix for SYBR® Green I Eurogentec, Seraing, Belgium 
AtlasTM Nylon rat 1.2 Clontech: BD Biosciences, Heidelberg, Germany 
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3.9 Fragment Length Standards  
RNA 6000 Ladder (0.2, 0.5, 1.0, 2.0, 4.0 and 6.0 kb) (Agilent Technologies, 
Waldbronn, Germany) 
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4 Methods  
4.1 Preparation of Total RNA  
The quality of RNA has a strong impact on the validity and reliability of the microarray 
experiment. Thus, it is essential to take all reasonable precautions and quality checks 
when preparing the samples for microarray experiments. Apart from the classical 
methods for RNA extraction, many commercial kits are available. 
4.1.1 RNA Extraction with GTC-Phenol-Chloroform  
Total cellular RNA was isolated from 50 mg homogenized lung tissue following the 
protocol of Chomczynski et al.59 Guanidine isothiocyanate (GTC)/phenol/chloroform 
based RNA extraction methods are very popular because they require much less time 
than traditional methods (e.g., CsCl2 ultracentrifugation). The GTC salt denatures the 
cellular proteins and inactivates RNases to ensure isolation of intact RNA. 
The lung tissue was fixed on the Tissue-Tek® and then 10 µm thin sections were cut in 
a tissue cryostat. The sections were collected in 1.5 ml Eppendorf tubes and 
homogenized by disrupting in 1000 µl of 4 M GTC buffer using a disposable syringe 
and 20 G sterilized needles. The Phase Lock Gel tubes (Heavy type, 15 ml, Eppendorf) 
were pre-spun for 2 min at 5,300xg. Afterwards, lysed material, 700 μl phenol pH 4.5, 
200 μl chloroform and 100 μl 2M NaOAc were added and vortexed. The mixture was 
centrifuged at 5,300xg for 20 min at 4°C. Upper phase was removed carefully and 
collected into fresh 1.5 ml Eppendorf tubes. For the RNA precipitation, 600 μl of cold 
isopropanol was added to the supernatant and incubated for 2 hours at -20°C. 
Samples were centrifuged at 14,000xg for 15 min at 4°C. The pellets were washed with 
75 % cold ethanol and air-dried. Finally, RNA was dissolved in 20 μl RNase free water. 
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4.1.2 RNA Extraction by TriFast™ / DNase Digestion / RNeasy 
Fifty mg tissue were sliced as mentioned 4.1.1 and was lysed in 1000 μl TriFastTM for 
10 min at room temperature. The lysed mixture was centrifuged for 5 min at 10,000xg, 
the upper phase was transferred into a new 1.5 ml Eppendorf tube. 200 μl chloroform 
were added, vortexed and incubated for 10 min on ice. After this, the samples were 
centrifuged for 15 sec at 16,000xg at 4°C. The upper phases were transferred carefully 
into fresh 1.5 ml Eppendorf tubes and mixed with the same volume of 75% chilled 
ethanol. Subsequent DNAse digestion and RNA purification was done using an 
RNeasy Miniprep column according to the manufactures instructions.  
4.1.3 RNA Extraction with the RNeasy Kit  
The basic principle of the RNeasy column technology is a combination of the selective 
binding properties of a silica gel-based membrane with the speed of microspin 
technology. 30 mg of lung tissue from the mice were used for the extraction. RNA was 
isolated and purified as per the instruction given for the Qiagen RNeasy Miniprep kit. 
4.1.4 Quality and Quantity Measurement  
RNA quality was analysed by microcapillary electrophoresis on Agilent LabChip®. For 
the Agilent LabChip analysis, 1μl of total RNA solution was loaded on RNA 6000 Nano 
Chip® and by following the steps given in the Agilent manual. The electropherograms 
of high-quality RNA show clear peaks for the 18S and 28S ribosomal RNAs. The 
electropherograms were checked for the absence of high-molecular nucleic acids that 
indicate contaminations with DNA.  
The total RNA quantification and purity was determined with a NanoDrop ND-1000 
spectrophotometer. The quantity of the isolated RNA was calculated from the 
absorbance at 260 nm and the purity was determined by the ratio OD260/OD280. Purity 
was considered good when the ratio was greater than 1.8. Low absorbance at 230 nm 
indicates the absence of salt.  
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4.2 Preparation of mRNA 
The preparation of mRNA was performed using the oligotex mRNA extraction kit. 25 µg 
total RNA were introduced to the mRNA extraction. Messenger RNA was purified as 
per the instruction given on mRNA mini kit from Qiagen. 
4.3 RNA Amplification  
Experiments involving glass microarrays typically require at least 20 µg of total RNA for 
cDNA labelling and subsequent hybridization. However, such amounts of RNA are not 
available from small precious samples obtained from laser microdissections or needle 
biopsies. However, small amounts of RNA can be preamplified to produce sufficient 
material for microarray experiments. The commonly applied preamplification 
techniques are: 
(a) T7-IVT (1-2 rounds) linear amplification 60-61 and 
(b) PCR-based exponential amplification 62-63 
4.3.1 T7-Based RNA Preamplification (T7-IVT) 
In 1990, van Gelder et al. described a protocol for linear RNA amplification from limited 
quantities of cDNA. Based on In-vitro transcription using T7-RNA polymerase, they 
were able to amplify RNA from heterogeneous populations by a factor of 103. Using 
this approach and by performing two rounds of linear RNA amplification, Eberwine et 
al. were able to profile the gene expression in single live neurons. 64 
Recently, a linear RNA amplification kit was developed (RiboAmp®, Arcturus) to amplify 
RNA from very small amounts of material. Using 2-3 µg RNA, one round of T7-IVT is 
argued to allow for a 1,000-fold amplification of mRNA, while two rounds shall permit a 
million-fold amplification of the mRNA. 
The amplification workflow is shown in figure 9. The procedure consists of reverse 
transcription with an oligo-dT primer linked to a T7-promoter sequence. Afterwards, 
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double stranded DNA is synthesized. Finally this DNA is then used as a template for 
the In-vitro transcription by T7 RNA polymerase. By providing labelled ribonucleotides 
in the reaction mixture, labelled aRNA is produced that can be used directly in 
subsequent hybridizations.  
AAAAA5’ 3’
3’(TTTTT) 5’ T7-oligo(dT)
AAAAA5’ 3’
(TTTTT) 5’3’
mRNA-poor sample
total RNA 
single-strand cDNA
Total RNA isolation
First strand cDNA synthesis
Second strand cDNA
synthesis
AAAAA5’ 3’
(TTTTT) 5’3’
double-strand cDNA
Cy3 *
Cy5 *
Cy-aRNAprobes
In vitro transcription 
& labelling
Protocol 1
*
*
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*
*
* *
*
*
**
*
*
* *
*
aRNA
In vitro
transcription
Reverse  transcription
& labelling
Cy-cRNAprobes
Protocol 2
Cy3 *
Cy5 *
 
Figure 9. Flow chart for the amplification and direct labelling method following the Acturus 
protocol (Picture adopted from http://arrays image. free.fr/The%20aRNA%20amplification.htm). 
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Starting with 50 ng total RNA from mice kidney, two rounds of T7-based RNA 
amplification were performed in triplicate using the Acturus kit. After the first strand 
cDNA synthesis, 6 µl of each reaction were taken off to serve as unamplified reference 
sample for the subsequent real-time PCR analyses. After preamplification, 4 µl aRNA 
each were reverse transcribed in 20 µl reactions. Each 6 µl cDNA were then used for 
real-time PCR analysis to compare unamplified and amplified material to calculate the 
amplification factors for specific target sequences.  
4.3.2 SMART™ based RNA Preamplification  
Alternatively, SMART™ (switching mechanism at the 5’ end of the RNA transcript) 
based RNA amplification is a PCR-based method suggested for producing high quality 
cDNA from nanogram quantities total RNA.65 The procedure is shown in figure 10. The 
amplification method consists of reverse transcription with a modified oligo-dT primer 
(SMART™ CDS Primer IIA) to initiate the first strand synthesis reaction. When reverse 
transcriptase reaches the 5’ end of the RNA, the enzyme’s terminal transferase activity 
adds a few additional nucleotides, primarily deoxycytidine, to the 3’ end of the cDNA. 
The next primer, SMART™ II, is an oligonucleotide with an oligo-dG sequence at its 3’ 
end to hybridize to the deoxycytidine stretch, creating an extended template for the 
reverse transcription. The reverse transcriptase then switches templates and continues 
replicating to the end of the oligonucleotide. The full-length single stranded cDNA 
contains sequences that are complementary to the BD SMART II A oligonucleotide. 
The BD SMART anchor sequences are then used as universal priming sites for full-
length cDNA amplification. 
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Figure 10. Flow chart shows the cDNA synthesis and amplification method (BD Atlas SMART™ 
fluorescent Probe Amplification Kit). 
For comparison of T7 and SMART™ based pre-amplification, SMART™ amplification 
was performed six times starting with 50 ng total RNA from mice kidney and liver. The 
preamplification was carried out using the SMART kit (Clontech) following the kit 
instructions. After the first strand synthesis, 6 µl of cDNA were taken off from each 
reaction to serve as the unamplified reference sample in the subsequent real-time 
PCR. Finally, dscDNA was purified with the QIAquick PCR Purification Kit. Each 6 µl 
dscDNA were then used for real-time PCR analysis to compare unamplified and 
amplified material to calculate the amplification factor. 
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4.4 cDNA Synthesis by Reverse Transcription  
cDNA synthesis was performed using 1-2 µg RNA. The RNA was redissolved in RNase 
free water to a volume of 10.5 µl. Samples were incubated for 10 min at 70°C for RNA 
denaturing and then rapidly cooled on ice. For cDNA synthesis, a mastermix was 
prepared using 4 µl MgCl2 (25 mmol/L), 2 µl 10X PCR buffer II, 1 µl dNTP (10 mmol/L 
each), 1 µl random hexamers (50 µmol/L), 0.5 µl RNase inhibitor (10 U), and 1 µl of 
MuLV (50 U). For the first-strand sythesis, the reactions were incubated for 10 min at 
20°C, 60 min at 43°C, and 5 min at 95°C.  
4.5 Real-time Quantitative PCR 
Real-time quantitative PCR for PBGD and GAPDH were performed using the ABI 7700 
sequence detection system. Each 50 µl-reaction contained 25 μl (2x) TaqMan 
Universal Master Mix supplemented by 4.5 μl forward and reverse primers (10 pmol/μl), 
1 μl dual-labelled fluorogenic probe (10 pmol/μl), 2 µl cDNA sample and 13 µl water. 
The cycling protocol was:  
 1x  50°C, 2 min  
 1x 95°C, 6 min 
 45x 95°C, 20 sec   
  60°C, 30 sec   
  73°C, 30 sec 
Whereas for the 3’ UTR-GAPDH, real-time PCR was performed using SYBR® Green I. 
Each 50 μl-reaction contained 25 μl (2X) PCR reaction buffer, 1 μl forward and reverse 
primers (200 nM), 1.5 µl of SYBR® green, 2 μl cDNA sample and 19.5 μl water. 
The cycling protocol was: 
 1X  95°C, 6 min 
 45X 95°C, 20 sec  
  60°C, 30 sec 
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 72°C, 30 sec with hold 60 
 95°C, 0.15 sec  
 40°C, 1 min  
The data was acquired after the extension phase at 73°C. Amplification curves were 
evaluated using the instrument’s software (SDS version 1.7) according to the analysis 
standards given in the manual. The crossing point data (Ct values) were exported to 
spread sheet software (Excel) for further analysis. 
The relative concentration of the target sequence in relation to the reference was 
expressed as 2ΔCt where ΔCt is the difference between the Ct values of the samples 
being compared.66 
4.6 DNA-Arrays  
4.6.1 Nylon Membranes 
4.6.1.1 Labelling: Generation of Radioactive Labelled cDNA 
6 µg total RNA were reverse transcribed by adding 1.2 µl CDS primer (AtlasTM Nylon 
arrays rat 1.2) and incubation for 5 min at 70°C. Reactions were then incubated for 10 
min at room temperature. The master mix supplied with the AtlasTM Nylon arrays rat 1.2 
kit for four samples were prepared by adding following ingredients: 20 µl 5X buffer, 4.5 
µl dNTP, 14 µl α-32P-dATP, 2.0 µl DTT (0.5 M) and 4.0 µl M-MLV reverse transcriptase. 
11 µl master mix were distributed to each sample. Afterwards, the reaction mix was 
incubated for 1 hr at 42°C. The reaction was terminated by heating to 70°C for 15 min. 
Radioactively labelled cDNAs were purified and eluted in 100 µl of elution buffer 
(supplied with AtlasTM Nylon arrays rat 1.2 kit). The activity was measured with a liquid 
scintillization counter (Hidex).  
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4.6.1.2 Hybridization 
The purified α-32P-labelled cDNA in elution buffer were hybridized on Rat 1.2 Atlas™ 
cDNA arrays nylon filters with 1,176 spotted cDNAs. Hybridization was carried out at 
68°C overnight. The filters were washed according to the manual. 
4.6.1.3 Scanning  
Filters were wrapped in plastic and exposed for 4-7 days to imaging plates (Fuji Photo 
Film) in a lead sheathing. The film was read out with a phosphoimager system. 
4.6.1.4 Analysis 
Raw data were collected using the AtlasImageTM 2.0 software. Values of spot 
intensities were adjusted by a global normalization using the sum method provided by 
the software. The mean global background was subtracted from the spot intensities.  
The log2-intensity values were normalized for each membrane by a Z-transformation. 
The normalized log-values were transformed back into intensity values (”Z”). Using the 
pair of Z values for the two spots on corresponding membranes, the value for the 
adjusted difference of the intensities is calculated by D=(Z2-Z1) / max (Z1,Z2), where 
max (Z1,Z2) is the greater one of the values Z1 and Z2. The codomain for the adjusted 
difference is limited in the range of –1 to +1. The Z values are not defined for 
background-corrected intensities smaller or equal to zero. It exist defined limiting 
values (i.e., the limits of the codomain) for the adjusted difference for the case that only 
one of the Z values is not defined, assuming a limiting intensity values of zero. Only 
when both of the intensity values are zero, the adjusted difference cannot be 
calculated. Genes were considered to be differentially expressed when both of the 
following criteria were fulfilled: 
p ≤ 0.10 of a one sample t-test with Ho: D=0 and H1: D ≠ 0 and  
|D| ≥ 0.30 (corresponding to a fold-change of ≥ 1.4) 
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4.6.2 Glass Microarrays 
4.6.2.1 Labelling: Generation of CyDye-Labelled cDNA by RT 
The following protocols describe RNA labelling with Cy3 and Cy5 dyes using four 
different reverse transcriptase enzymes, see table 7 a while table 7 b show steps for 
direct labelling using Klenow DNA polymerase.  
Table 7. (a) Pipetting plan for target labelling during RT. 
 Amersham 
CyScribe 
Invitrogen 
Fluoroscript 
Qiagen 
Ominiscript 
Invitrogen 
Superscript II 
RNA (25µg) 10 4 12 17 
Oligo dT (µl) 1 1 0.5 1.5 
Volume (µl) 11 5 12.5 18.5 
Step 1 70°C, 5’ 
RT, 10’ 
70°C,  
Ice, 10’ 
- 65°C, 10’ 
RT, 10’ 
5X Buffer (µl) 4 4 - 8 
10X Buffer - - 2 - 
0.1M DTT (µl) 2 2 - 4 
dCTP nucleotide Mix 1 - - - 
dNTP (5mM dATP, 
dGTP, dTTP, 2 mM 
dCTP) (µl) 
- 1 0.4 4 
1 mM Cy3/Cy5 dCTP 1 2 2 4 
RNAse-inhibitor 
(40U/µl) 
-  1.0 - 
Enzyme 1 1 1.5 1.5 
Water - 5 0.6 - 
Total Volume (µl) 20 20 20 40 
Step 2 42°C, 90’ 50°C, 60’ 37°C, 90’ 
95°C, 10’ 
39°C, 120’ 
200mM EDTA (µl)          - 2 - - 
2.5 M NaOH (µl) 2 - - - 
1M NaOH (µl) - 21 - 102 
2M HEPES (µl) 103 - - - 
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 Amersham 
CyScribe 
Invitrogen 
Fluoroscript 
Qiagen 
Ominiscript 
Invitrogen 
Superscript II 
TE (pH 7.5) - 1 - 200 
1M HCL - 2 - 10 
1MTris/HCL pH 5 (µl)  - 1 - - 
1 following incubation for 10’ at 70°C 
2 following incubation for 10’ at 65°C 
3 following incubation for 5’ at 37°C 
(b) Direct labelling with Klenow DNA polymerase. 
dscDNA (2µg) (µl) 10  
Random hexamer @ 5mg/ml (µl) 2  
Mili Q water (µl) 8  
Tolal volume (µl) 20 
Step 1 95°C, 5’; ice, 5’ 
10X Klenow buffer 4  
dNTP mix (5mM dATP, dGTP, dTTP, 2 mM 
dCTP) (µl) 
 
5  
1mM Cy3 or Cy5-dCTP (µl) 2  
Klenow polymerase (µl) 1.5  
Mili Q water (µl) 7.5  
Adjusted total volume (µl) 20  
Step 2 37°C, 2 hrs 
0.5 M EDTA (µl) 5  
 
After the labelling reaction, labelled cDNA was purified with the PCR Purification Kit 
according to the kit protocol.  
4.6.2.2 Labelling: Generation of CyDye-Labelled aRNA by T7-IVT 
Each two samples of 50 ng total RNA from mice kidney and liver were amplified by T7-
IVT as described in section 4.3.1. aRNA from kidney and liver (n=2) were labelled with 
Cy5 and Cy3 dyes as follows: 4 µl IVT buffer, 6 µl IVT master mix, 2 µl IVT enzyme, 
and 1.2 µl Cy5/Cy3-UTP (0.50 mM) mix were added during the 2nd round IVT process 
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in a total reaction volume of 24 µl. The amplification and labelling reaction together 
were incubated for 4 h at 42°C. Finally, the labelled aRNA was purified in 30 µl using 
the columns provided with the kit. 
4.6.2.3 Labelling: Generation of CyDye-Labelled dscDNA by SMART™ 
Each two samples of 50 ng total RNA from mice kidney and liver (n=2) were introduced 
to SMART™ based amplification with 15 cycles as described in section 4.3.2. The 
samples (dscDNA) were finally purified with the QIAquick PCR Purification Kit. The 
purified dscDNA was labelled following the kit protocol. Briefly, this indirect labelling 
procedure is performed in two steps:  
The first step produces aminoallylated DNA: 500 ng dscDNA were diluted in 76 µl of 
sterile water. A reaction mix composed of 10 µl 10X random primer mix (N-18), 2 µl 
10X Labelling dNTP Mix, 10 µl 10X BD Advantage™ 2 PCR Buffer and 2 µl 50X BD 
Advantage™ 2 polymerase Mix were added to get a final volume of 100 µl. The PCR 
reactions were performed using the following programe: 95°C 5 min, 3 cycles: 94°C 1 
min, 25°C 1 min 30 sec, 50°C 10 min, 68°C 5 min. The reactions were terminated by 
adding 0.5 µl 0.5 M EDTA (pH 8.0). After 10 µl quick clean resin solution were added, 
the PCR products were purified through 0.22 µm spin filters. The supernatant from 
each reaction was collected after centrifugation. For precipitation, 11 µl of 3M NaOAc 
together with 275 µl 100% ethanol were added and incubated for 1 hr at -20°C. The 
Pellets were washed with 70% ethanol and finally dissolved in 10 µl 2X fluorescence 
labelling buffer. 
The second step couples the monoreactive dyes: 5 mM fluorescent dye stock was 
prepared by adding 45 µl DMSO directly to the Cy3 and Cy5 reactive dye. Afterwards, 
10 µl of the DMSO/dye mixture were added to the aminoallylated cDNA sample and 
incubated for 30 min at room temperature in the dark. 2 µl of 3M NaOAc together with 
50 µl 100% ethanol were added and incubated for 2 hr at -20°C to precipitate the 
cDNA. The pellets were washed with 70% ethanol and dissolved in 100 µl nuclease 
free water. Finally, the samples were purified with the QIAquick PCR Purification Kit. 
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4.6.2.4 Quality and Quantity Control of Labelled Products 
For all labelled samples, CyDyes-labelled products quality and quantity were measured 
on nanodrop spectrophotometer. The quality of the labelling was estimated by the 
shape of the absorbance spectra (figure 11) and by the incorporation rate of 
fluorescent molecules.  
 
Figure 11. OD-Spectrum of a mixture of Cy3- and Cy5-labelled cDNAs (Screenshot taken from 
the Nanodrop software). The peak heights at 550 nm and 650 nm correspond to the amount of 
Cy3 and Cy5, respectively. 
The frequencies of incorporation (FOI) in CyDye molecules per kb were calculated 
from the measured absorbance values by the following formulas: 
for Cy3: OD550  / OD260  x 58.5  
for Cy5: OD650 / OD260 x 35.1 
4.6.2.5 Slide Preprocessing, Hybridization and Washing 
Typically, cDNA spotted slides from the DKFZ need to be prewashed before 
hybridization. The slides were prewashed by dipping the slides for 2 min each into  
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1. 0.2 % SDS  
2. Double distilled water (RT) 
3. Double distilled water (95°C)  
4. 100% ethanol 
Finally, slides were dried by with compressed air or by centrifugation. 
For the mouse 10K and rat 10K oligonucleotide-spotted glass slides, 25 pmol each Cy3 
and Cy5 labelled sample were pooled. The volume of the pooled samples was 
adjusted to 15 µl. The hybridization buffer was preheated to 42°C before the labelled 
samples were added and the complete mix was then first incubated for another 3 min 
at 42°C, then for 3 min at 95°C, and finally for 3 min at 4°C. The hybridization was 
carried out at 42°C for 16 h in the PerkinElmer hybridization station with enabled 
agitation. After hybridization, the slides were either washed automatically in the station 
or removed and washed manually. The protocol for machine washing is shown in table 
8. 
Table 8. Machine washing protocol. 
Buffers  Flush (µl) Cycle 
numbers 
Temp. (°C) Time  (sec) Hold 
2X SSC, 0.1% SDS 500 3X 42 30 2’ 
1X SSC 500 3X 25 30 2’ 
0.5X SSC 500 2X 25 30 2’’ 
 
The manual washing was done by dipping the slides one by one into 200 ml of buffer 1 
(2X SSC, 0.1% SDS), buffer 2 (1X SSC), and buffer 3 (0.5X SSC) for 5 min each. 
Slides were dried using centrifugation and scanned. 
4.6.2.6 Tests to minimize unspecific fluorescence 
To minimize the high fluorescence background on the slides, following parameters 
were tested: 
1) Buffers  
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Two slides from each i.e. cDNA (DKFZ) spotted and Oligospotted (MWG), were tested 
in a three different series of set of buffers (see section 5.1.4.1). Slides were manually 
washed and were dried by centrifugation.  
2) Ethanol brands 
Three normal glass slides were dipped in a 200 ml of two different brands of ethanol. 
Slides were dried by centrifugation. 
3) Canned and compressed air  
Six normal glass slides were dipped in 200 ml of double distilled water. Three slides 
each were dried with canned air and by comperssed air, respectively.  
4) Washing 
Several slides were washed manually as well as automatically. The scans were 
compared. 
4.6.2.7 Scanning  
All hybridized arrays were scanned at a resolution of 10-µm utilizing an Axon 4100A 
GenePix scanner. The gain settings for the photomutiplier tubes were adjusted to use 
the entire dynamic range of the instrument and to get comparable fluorescence yield in 
both channels. Images of Cy3 and Cy5 signals were recorded as 2 layer 16bit TIFF-
files and analysed using GenePix Pro 5.0. 
4.6.2.8 Analysis 
Spots that showed artefacts such as irregularities or spots covered by dust particles 
were flagged "bad" and so removed from further analysis. For all data, the local 
background was subtracted from the intensity values of each spot on the array. The 
data were analysed using R 1.9.1 and the “limma” package.67-70   
Spots were weighted by foreground/background – ratio, homogeneity, and saturation. 
Sigmoid functions were designed to get weighting-factors between 0.0 (bad) and 1.0 
(good) depending on the quality criteria (see figure 12)  
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Figure 12. Spot weight functions use for microarray analysis.  Left: relative signal intensity, 
middle: spot homogeneity, right: saturation. 
Factors were calculated for each channel individually and the smaller factor was taken 
for subsequent calculations. The final weighting factor was the product of the three 
quality-specific factors. 
An ‘MA-plot’, as described in Dudoit et al.,71 is used to represent the data. R and G 
values are the mean of the foreground intensity minus median of the background 
intensity at 535 nm (Cy3) and 635 nm (Cy5). M values express the log fold-change or 
log ratio (M = log2(R/G)), whereas A values represent the average log intensity (A = 
½·log2(R·G)). MA-plots are helpful to identify intensity-dependent artifacts. Although 
MA-plots are straight-forward, the very high correlation between the two channel 
intensities always dominates the plot making the more interesting features of the plot 
difficult to discern. It also displays the important relationship between differential 
expression and intensity that is used in later analysis steps. 
The data were corrected for intensity dependent artifacts by subtracting a weighted 
LOESS function (locally weighted scatter plot smother).72 The effect of the LOESS 
correction is shown in figure 13.  
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Figure 13. An MA-plot. An example shows distribution of expression values before and after 
loess correction.  
After the LOESS correction has been performed, the corrected expression values were 
averaged over the technical and biological replicates using the linear model fit of the 
“limma” package.73 The probability of differential expression was estimated using the 
Bayesian approach with a fraction of 0.1% of the genes being estimated to be truly 
differentially expressed. Genes were considered to be differentially expressed 
(selected) when the Bayesian odds-ratio was greater than 1. 
4.6.3 Affymetrix GeneChips 
4.6.3.1 Labelling: Generation of Biotinylated cRNA 
From each in-vivo (IT and IV) and ex-vivo (IT and IV) group, 15 µg total RNA were 
amplified by T7-based RNA preamplification and labelled with biotin using the 
Affymetrix target labelling protocol (see figure 14). 
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Figure 14. Target amplification and labelling procedure (Picture taken from www.affymetrix.co 
m) 
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4.6.3.2 Hybridization, Scanning and Analysis 
cRNA quality and quantification were measured on nanodrop spectrophotometer as 
described in section 4.6.2.4. Hybridization, scanning and data analysis were done at 
Max-von-Pettenkofer Institute, München by R. Hoffmann. Cluster analysis on the 
analysed data was performed using the dChip software.74 
4.7 Animal Models 
4.7.1 Monocrotaline Rat Model 
All preparations were done at the laboratory of PD Dr. R. Schermuly, Department of 
Internal Medicine, University of Giessen, Lung Center. Male Sprague-Dawley rats 
weighing 300–450 g were used in the study. MCT was dissolved in 3 ml of 1N HCl, the 
pH was adjusted to 7.4 with 2 ml of 1N NaOH. 600 ml solution was given in a single 
subcutaneous injection (60 mg/kg) to male rats. Three groups with 3 animals per group 
were studied for chronic aspects:  
1) Control28: control animals treated with isotonic saline were kept for a period of 28 
days 
2) MCT28: animals treated with MCT were kept for a period of 28 days;  
3) MCT28 / tolafentrine14–28: like group 2 but were additionally treated with tolafentine 
from day 14-28; 
4) Tola14,: animals treated with tolafentrine for a period of 14 days. 
The animals of the control28 and tola14 groups were first anesthetized with fentanyl and 
metedomidine (300 and 300 µg/kg IP) and then subjected to the implantation of the 
mini pump in the dorsal subcutaneous region. This allowed a continuous application of 
NaCl (for control group) or 5 mg/ml tolafentrine per day, respectively. After 4 weeks, 
the rats were anesthetized with sodium pentobarbital (50 mg/kg, ip). The lungs were 
perfused, harvested and immediately stored in liquid nitrogen.  
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4.7.2 Pneumolysin Mice Models 
4.7.2.1 Pneumolysin Animal Model 
Female 8-12 weeks old BALB/c mice between were used for all the experiments. The 
animals were prepared by the group of PD Dr. U. Maus, Department of Internal 
Medicine, University of Giessen, Lung Center. Three mice each were instilled with 200 
ng pneumolysin via intratracheally (IT) or intravenously (IV), respectively. Two 
untreated mice served as control. After 24 h, the mice were anesthetized. The lungs 
were perfused with Hank’s balanced salt medium (HBSS) free of calcium and 
magnesium and harvested from the animals. IT treatment of PLY resulted in severe 
illness and respiratory distress. Systemic (IV) PLY application showed no effect on the 
health state.  
4.7.2.2 Pneumolysin Organ Model 
All isolated lung preparations were done at the laboratory PD Dr. N. Weissmann, 
Department of Internal Medicine, University of Giessen, Lung Center. Three lungs each 
were instilled for 2 hrs with 200 ng pneumolysin via IT or IV, respectively. Two 
untreated organs served as a control. Lungs were ventilated and perfused artificially. 
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5 Results  
5.1 Technical Aspects 
5.1.1 RNA Extraction Methods 
Preparation of high quality RNA is the first and one of the most critical steps in 
performing microarray experiments successfully. Several methods can be employed to 
extract RNA from tissue and cells,75-78 and for most of them kits are available. Three 
methods were tested to compare their reliability as well as the yields, qualities and 
purities of the isolated RNAs. Table 9 shows the results of the three different extraction 
methods tested. 
Table 9. Results of different RNA extraction methods.  
 GTC based  RNeasy column Trifast/column/DNase 
Tissue  Rat lung Rat lung Rat lung 
Tissue introduced  50 mg 30 mg 60 mg 
Total isolation time 5 h 30 min 4 h 
Number of repetitions 4 3 4 
OD260 / OD280  2.0 1.6 2.0 
RNA yield total1 ~35 µg  ~20 µg ~100 µg 
RNA yield µg/mg tissue 0.7 0.7 1.7 
1 an average amount was calculated for each methods. 
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Figure 15. Microcapillary electropherograms of isolated RNAs. Top: GTC-method, middle: 
Trifast/column/DNAse-method, bottom: RNeasy column-method. RFU: relative fluorescence 
units. 
The integrity of the RNA was estimated from the peaks of the 28S and 18S rRNAs in 
the electropherograms (figure 15). The integrity of RNA isolated with both the GTC–
and the Trifast/column/DNase-method were comparably good whereas the RNA 
isolated with the RNeasy column seemed to be highly degraded.  
18
S
28
S
18S
28S
18
S
28
S
18
S
28
S
18
S
28
S
28S
18S
28S
18S
Time (s)
R
FU
 
R
FU
 
R
FU
 
18 S
18 S
28 S
28 S
  46
5.1.2 Reverse Transcriptases for Direct RNA Labelling 
For RNA labelling, many protocols as well as commercial kits are available.79 To obtain 
labelled single strand cDNA, RNA is usually reverse transcribed in the precence of Cy-
labelled deoxynucleotides. More than 20 pmol fluorescently labelled cDNA with more 
than 10 labelled nucleotides per 1000 nucleotides are required to get acceptable 
fluorescence signals on high-density microarrays.80 The yield of a labelled sample 
depends on fidelity of the reverse transcriptase to synthesize cDNA and to incorporate 
dye-coupled nucleotides. Four different reverse transcriptases were tested for their 
suitability to generate labelled cDNA (figure 16).  
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Figure 16. Labelling performances of different reverse transcriptases. (A) Yields of incorporated 
dye. (B) Frequencies of incorporation. 
The yield of incorporated dyes was between 10 and 35 pmol, the values for the FOI 
ranges between 5 and 15 dye molecules per kb. The FOI was not determined for the 
CyScribe™ enzyme because the protocol includes the addition of carrier nucleic acids 
that mask the cDNA, hence the FOI cannot be calculated. All enzymes perfomed 
comparably well, but SuperScript II enzyme resulted in slightly higher values. 
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5.1.3 Direct and Indirect Labelling 
Protocols for direct and indirect labelling were compared to investigate which method 
results in a higher incorporation rate, and thus, a higher yield of fluorescence. 2 µg 
dscDNA were introduced i) for the direct labelling using Klenow DNA polymerase (n=3) 
and ii) for indirect labelling (n=3) using Super SMART™ kit (with the Taq DNA 
polymerase).  
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Figure 17. Comparison of direct and indirect labelling protocols.  
Indirect labelling with the SMART™ kit turned out to be more productive than the direct 
labelling method (figure 17). With the indirect method on average ~90 pmol dye 
mulecules were incorporated in the products per reaction. The direct labelling using 
Klenow DNA polymerase yielded an average of ~19 pmol incorporated dye molecules. 
The average FOIs were ~11 CyDyes/kb for the indirect labelling and ~7.5 CyDyes/kb 
for the direct labelling. 
5.1.4 Optimization of Hybridization and Washing 
A number of factors, e.g., contaminating fluorescent particles, SDS, and temperature, 
can affect the hybridization and may contribute to high fluorescence background (see 
figure 18) that can impair the results of microarray experiments.  
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Figure 18. High background. Mouse cDNA slides show high fluorescence background at 550 
nm (A) and at 650 nm (B). 
5.1.4.1 Buffer Test 
Following buffers tests (table 10) were performed in order to select the reliable set of 
wash buffer. 
Table 10. Buffers tests. 
 Buffer 1 Buffer 2 Buffer 3 Green 
fluorescency 
observed 
DTest 1 
 
0.5X SSC,  
0.1% SDS for 5’ 
0.05X SSC, 
0.1% SDS for 5’ 
0.05X SSC for 
5’ 
Yes 
DTest 2 2X SSC,  
0.2% SDS for 5’ 
2X SSC for 5’ 0.2X SSC for 5’ Yes 
D+MTest 3 
 
2X SSC, 
 0.1% SDS for 
5’ 
1X SSC for 5’ 0.5X SSC for 5’ No 
D  Performed with DKFZ only 
D+M Performed with DKFZ and MWG 
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Using slides from cDNA spotted from DKFZ and oligospotted from MWG, test 3 did not 
show green fluorescency smear on to the slides while using slides from DKFZ, test 1 
and 2 showed fluorescency. 
5.1.4.2 Influence of Ethanol  
cDNA glass slides need to be treated with a series of washing steps before 
hybridization including a last incubation step with 100% ethanol to dry the slides. 
Ethanol has been discussed as a source of unspecific fluorescence.81  
 
Figure 19. Influence of ethanol brand. Test slides with (A) ethanol from Merck and (B) ethanol 
from Sigma-Aldrich.  
Three test slides each were dipped in 100% ethanol from Merck and from Sigma-
Aldrich, respectively. The slides were dried and scanned. The slides dipped in the 
ethanol from Merck show a bright background fluorescence in the Cy3 channel (green) 
on the slides (figure 19 a), whereas the scans of the slides treated with the ethanol 
from Sigma-Aldrich did not show green smear at all (figure 19 b).  
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5.1.4.3 Influence of Canned Air 
The slides have to be dried after washing. Using canned air for this purpose resulted in 
a remarkable increase in green background fluorescence (figure 20 a), whereas slides 
dried by compressed air (figure 20 b) or by centrifugation did not show any background 
fluorescence. 
 
Figure 20. Influence of canned air. After drying (A) with canned air and (B) with compressed 
air. 
Interestingly, background fluorescence was observed only when canned air was 
sprayed on wet slides. Excessively spraying of canned air on dry slides did not result 
in background fluorescence.  
5.1.4.4 Influence of the Washing Procedure 
The purpose of stringency washing is to minimize the background by removing 
hybridization buffer and unhybridized or wrongly hybridized labelled cDNA. The slides 
were washed in a series of buffers initially with low-stringency wash buffer (2XSSC; 
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0.2%SDS), then with high-stringency wash buffer (1X SSC), and finally with post-wash 
buffer (0.5% SSC).  
 
Figure 21. MWG test slides. Scanned images after (A) machine-washing and (B) manual 
washing. 
The glass slides washed in the PerkinElmer hybridization station (as described in 
section 4.6.2.5) showed unexpected high green fluorescence background masking 
almost all gene signal intensities (figure 21 a). In contrast, manually washing by quickly 
transferring them into a series of buffers resulted in clean slides with almost no 
background fluorescence (figure 21 b). 
5.1.5 Quality of cDNA Spotted and Oligonucleotide Spotted 
Glass Arrays 
After optimization of slide-washing and slide-drying parameters, next aim was to 
compare cDNA versus oligonucleotide spotted slide quality in terms of reliability and 
reproducibility. For such comparison we used slides from three different companies:  
(a) DKFZ (40K Mouse) cDNA spotted 
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(b) MWG (10K Rat, 10K Mouse) oligospotted  
(c) Agilent (22K Mouse) oligospotted 
In all experiments, cDNA containing 25 pmol of incorporated Cy3 and Cy5 molecules 
were hybridized. 
 
Figure 22. Survey and spot details of different microarray slides. (A) DKFZ cDNA 20K in 
duplicate (=40K) spotted array. (B) MWG 10K oligospotted array. (C) Agilent 22K oligospotted 
array.  
Hybridization was performed for 16 hours on the PerkinElmer hybridization station 
(DKFZ cDNA-spotted slides at 42°C, oligo-spotted slides from MWG at 42°C, oligo-
spotted slides from Agilent at 42°C). Slides were scanned with the Axon scanner. The 
DKFZ slides (figure 22 a) suffer high background and irregular spot morphologies. In 
contrast, the MWG and Agilent slides (figure 22 b, c) showed less background and had 
regular, homogenous spots.  
Slide quality was analysed on the basis of: i) signal-to-noise ratios, ii) standard 
deviations of the within-spot ratios, and iii) spot morphology (homogeneity i.e. the 
relative difference of mean to median spot intensity is a good measure for 
homogeneity) (figure 23). 
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Figure 23. Quantitative results of the slide quality measures. All Diagrams show the median 
and center 50% of the values for one representative slide. The whiskers include the center 90% 
of the values. (A) Ratio-SD: For each spot on the slide, the standard deviation of the log-ratios 
of red and green signal intensities for each pixel was calculated. (B) Normalized difference of 
the mean and the median of the foreground intensity (both channels averaged) of the spots. 
Deviation from zero indicates inhomogeneous intensity distributions whitin the spots. (C) And 
(D) Logarithms of the signal-to-noise ratios (SNR = foreground / background intensity) for each 
channel. 
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5.1.6 Preamplification 
The requirement of a large amount of high-quality RNA is a major limiting factor for 
microarray experiments using RNA from biopsies or from laser microdissection. An 
average microarray experiment requires about 20 µg of total RNA for cDNA labelling 
and subsequent hybridization.82-83 However, microdissected cells and small biopsied do 
not yield such amounts. Several different approaches for RNA preamplification have 
been described and applied for microarray studies. Especially for the combination of 
laser microdissection and microarrays, low amounts of RNA have to be preamplified.84 
Therefore, we compared the yields and biases of the T7-IVT and SMART™ using 
limited starting material (~50 ng total RNA). 
5.1.6.1 Assessment of Product Length 
Quantitative real-time PCR was performed on aliquots of the samples before 
(reference) and after preamplification to determine the amplification factors of three 
target sequences with different distances to the poly-A-tails. The analysed target 
sequences are 3’UTR-GAPDH, GAPDH and PBGD with 200 bp, 700 bp, and 1400 bp 
distance to the poly-A-tail. The results are given in table 11 and figure 24. 
Table 11. Quantitative PCR results of the preamplification experiments. The values are rounded 
to 2 significant digits. 
  SMART   T7   Target 
(3’-distance [bp])   12 cycles 24 cycles   2 rounds   
GAPDH 3’-UTR
(200)   
10.5 ± 2.3 
(7.9..13)  
16.2 ± 3.2 
(13..19)   
9.8 ± 0.9 
(7.6..12)  
ΔCt mean ± sd
(90%-CI)1 
    1500 (230..9500)  
75000 
(8980..625838)   
870 
(200..3900)  
factor mean2 
(90%-CI) 
GAPDH 
(700)   
6.8 ± 0.8 
(5.8..7.8)  
13 ± 1.4 
(12..14)   
7 ± 0.4 
(6.1..7.9)  
ΔCt mean ± sd
(90%-CI) 
    120 (58..230)  
8500 
(3300..22000)   
130 
(67..250)  
factor mean 
(90%-CI) 
PBGD  
(1400)   
11.8 ± 1.8 
(8.8..15)  
17.6 ± 1 
(16.0..19.3)   
2.8 ± 0.7 
(1.0..4.6)  
ΔCt mean ± sd
(90%-CI) 
    3500 (460..28000)  
200000 
(65000..650000)   
7 
(2..24)  
factor mean 
(90%-CI) 
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1 ΔCt = corrected difference of the Ct values determined with real-time PCR before and after 
preamplification; SD=standard deviation; 90%-CI=90% confidence interval using the t-
distribution. 2 factor mean = 2(mean ΔCt) 
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Figure 24. Quantitative PCR results of the preamplification experiments. Mean ∆Ct values 
(unamplified – amplified) for 3’UTR-GAPDH, GAPDH and PBGD, showing the comparison 
between 2 rounds of T7 and SMART™ (12 and 24 cycles) based amplification. The error bars 
indicate the standard deviation (n=3..5). Inlet: positions of the target sequences within the 
analysed transcripts. 
Mean ∆Ct values for 3’UTR-GAPDH and GAPDH with 12 cycles and two rounds of T7-
IVT were comparable within the margins of error (table 11). However, the PBGD target 
sequence that was positioned 1400 bp away from the poly-A tail was efficiently 
amplified by SMART™, whereas T7-IVT almost failed to amplify this sequence. The 
expected ∆Ct values for the SMART™ amplification are the number of amplification 
cycles performed (i.e., 12 and 24, respectively). After 12 cycles of SMART™ 
amplification, the expected ∆Ct was reached for 3’-GAPDH and for PBGD, whereas the 
∆Ct value obtained for GAPDH was considerable lower (90%-CI: 6..9, see table 11). 
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Furthermore, an increase of the number of amplification cycles to 24 resulted in a 
further increase of the amount of product. However, all ∆Ct values for 24 cycles 
SMART™ were significantly lower than the ideally expected value of 24, indicating that 
the amplification reaction was already reaching the plateau phase. Notably, the relative 
differences of the amplification factors of the different target sequences are similar to 
those after 12 cycles of SMART™. 
5.1.6.2 Comparison of Preamplification Techniques for Expression Profi-
ling using DNA-microarrays  
To assess which preamplification technique is more suitable for expression profiling 
using DNA microarrays with limited material, both techniques (SMART™ and T7-IVT) 
were compared. Potential amplification bias was estimated by the comparison to 
directly labelled cDNA from unamplified RNA as reference. 50 ng total RNA from each 
mouse liver and kidney were introduced using T7-IVT (2 rounds) and SMART™ (15 
cycles) techniques. Two rounds of T7-IVT and 15 cycles SMART™ yielded about 50 µg 
aRNA with ~2000 pmol dyes and 1.5-2.0 µg dscDNA with ~40 pmol dyes, respectively. 
The introductory amount of sample used for expression profiling was adjusted to 25 
pmol each Cy3 and Cy5 incorporated dyes. Labelled samples were hybridized on 
mouse 10K 50mer oligonucleotide microarrays. The whole procedure including 
preamplification, labelling, and hybridization was done twice to get results for two 
completely independent experiments. 
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Figure 25. Comparison of microarray images. Labelled samples from mouse kidney and liver 
were hybridized on 10K mouse arrays from MWG. (A) Reference (unamplified), (B) SMART™ 
(15 cycles) and (C) T7-IVT (2 rounds). 
A representative area of the scanned images (figure 25) provides a first hint that the 
expression profile after SMART™ is more comparable to the reference than after T7-
IVT. Although the same amount of fluorescence was used for all hybridizations, many 
spots were missing after T7-IVT. 
The reproducibility of the preamplification was estimated by a comparison of the 
expression profiles obtained from the two independent experiments. A direct 
comparison of the M values (log2 ratios liver vs. kidney) for all features on the slides for 
the same method (reference, SMART, and T7-IVT) is shown in figure 26. 
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Figure 26. Scatter plots of the M values of slide 1 versus slide 2. R=Pearson’s coefficient of 
correlation. 
Spots with weight factors greater than 0.75 were considered for further analysis. Intra-
assay comparison was assessed by the Pearson’s correlation coefficient (R2) of the M 
values of the two slides for each method. The within-method correlation coefficients for 
reference (R=0.87) and SMART™ (R=0.9) were comparably well, whereas the value of 
R for T7-IVT was clearly lower (R=0.66).  
To analyse the correlation of the M values between the preamplification methods, the 
M values of the two independent experiments within each method were averaged. The 
scatterplots for the comparison of either amplification method with the reference are 
shown in figure 27. The values obtained for Pearson’s correlation coefficient were 0.92 
for SMART™ and 0.68 for T7-IVT. The observed dynamic range of differential 
expression (=range of M values) seems to be limited. 
 
R=0.861 R=0.9 R=0.661 
Reference SMART T7-IVT 
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Figure 27. Scatter plots for the M values. Left: SMART™ versus reference and right: T7-IVT (2 
rounds) versus reference. 
Figure 28 shows the M/A-scatterplots for the averaged data of the two slides per group. 
Using the odds ratio for M≠0 and the absolute average M value as selection criteria, 57 
genes are selected in the reference, 316 are selected for SMART™, and 62 genes are 
selected for T7-IVT (red points in figure 28). In “real” experiments, these selections 
would indicate the genes considered as differentially expressed. 
 
Figure 28. M/A-Scatterplots for the averages. Red: genes with an odds-ratio for M≠0 greater 
than 1 and |M| greater than 1 that were selected as differentially expressed.  
The Venn diagram in figure 29 (left side) shows that 41 selected genes were common 
in reference and SMART, 2 selected genes were common in reference and IVT, 10 in 
R=0.852 R=0.536
SMART versus Reference T7-IVT versus Reference 
Ref SMART T7-IVT 
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SMART and IVT and none of the selected genes were common in reference, SMART 
and IVT, respectively. The selected genes were validated using the information about 
their differential expression between liver and kidney in the two public databases.85 The 
sets of genes listed in the databases were not identical. The differential expression of 
those genes listed in both the databases was assigned similarly in both databases. The 
results are shown in figure 29 (right side). 
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Figure 29. Venn diagrams and number of selected genes found in databases. Ref = 
Reference; NA = not assigned as differentially expressed or not present in the databases. Blue: 
number of correctly selected genes (present in the databases and correctly assigned in 
differential expression); red: number of falsely selected genes (present in the databases but 
with the opposite differential expression); gray: number of selected genes not present in the 
databases. 
As figure 29 (right one) shows for the reference experiment with unamplified RNA, out 
of 97 significantly regulated genes, 56 genes were truly differentially expressed (shown 
with purple color), 7 were false genes (red color) and 34 genes were not available 
(grey color) as per databases search. For IVT, out of 62 significantly regulated genes, 
18 were truly differentially expressed, 4 were false genes and 40 genes were not 
available as per databases. However, for SMART, out of 315 significantly regulated 
genes, 187 genes were truly differentially regulated which was 3X to the reference and 
9X to the T7-IVT samples, with a least number of false genes (5 %) and 112 genes 
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were not available as per databases search. In conclusion, expression profiling after 
SMART™ based preamplification turned out to be more efficient, reliable and 
reproducible than T7-IVT. 
5.2 Microarray Application in Animal Models 
5.2.1 Monocrotaline Induced Pulmonary Hypertension 
Monocrotaline (MCT) induced pulmonary hypertension (PH) is characterized by lumen-
obliterating endothelial cell proliferation and vascular smooth muscle hypertrophy of the 
small precapillary pulmonary arteries.  
In a rat model, subcutaneously injected MCT induces endothelial inflammation and 
structural remodelling of the lung arteries leading to PH with similar histological 
properties as seen in human PAH. Tolafentrine is known to attenuate the abnormalities 
in hemodynamics and gas exchange and the right-heart hypertrophy. Tolafentine is a 
phosphodiesterase inhibitor and possesses a strong antiproliferative effects in the 
pulmonary circulation.47  
Following conditions were investigated compared to a control group without any 
treatment: 
i) MCT28 (MCT): After systemic application of MCT animals are sacrificed at day 
28: MCT application induces an endothelial inflammation with a structural 
remodelling of the lung arteries leading to pulmonary hypertension within 28 
days. 
ii) MCT28+Tola14 (MT): 28 days systemically applied MCT: 14 days after systemic 
application of MCT tola is continuously infused for further 14 days. The animals 
are sacrificed at day 28.  
iii) Tola14 (tola): Control group with tola infused from day 14 to day 28 (without 
MCT application). 
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The expression profile of MCT-induced and tolafentrine-attenuated PH in the rat lung 
tissue was analysed using nylon filter arrays with 1176 cDNA probes (Atlas) as well as 
glass microarrays with 10K oligonucleotide probes (MWG). 
5.2.1.1 Expression Profiles on Nylon Filter Arrays 
Hybridization was performed on Atlas Rat 1.2 Array (1,176 spotted cDNAs). Two 
groups i.e. MCT (n=3) and MT (n=2) respectively were hybridized using control group 
as a reference. Figure 30 shows a representative scanned image of nylon filters. 
A                                                B   
 
Figure 30. cDNA macroarray nylon filter. Left side: duplicate control, Right side: duplicate 
MCT treated sample. 
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The intensity dependent data distribution is shown in figure 31.  
 
Figure 31. D/A-Scatterplots for the averages. Control used as a reference for (A) MCT and (B) 
MT. Red dots: selected genes. 
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From 703 evaluated genes (where at least one spot was above background), 11 genes 
were considered to be differentially expressed according to the selection criteria 
applied (4.6.1.4) after MCT treatment. Similarly, 3 genes from 379 genes were selected 
in the MT group (see table 12).  
Table 12: Selected Genes from the Nylon Macroarray Experiments. N: number of experiments, 
A: adjusted differences, M: average log2 intensity, P: p-values, SD: standard deviation of D 
Gene GenBank 
Accession 
N A M D P SD
MCT versus Control 
MXI1 AF003008 2 -0.08 -0.79 -0.41 0.0361 0.033
PKB; AKT1 D30040 3 0.43 -0.57 -0.32 0.003 0.031
FABP4; ALBP U75581 3 0.69 -0.54 -0.31 0.0303 0.095
GLCLC; g-ECS J05181 2 -0.53 -0.69 -0.38 0.0001 <0.001
alkaline phosphatase J03572 2 1.41 0.70 0.38 0.0181 0.015
neurotensin receptor 2 U51908 2 0.12 0.60 0.34 0.0217 0.016
GABRA1 L08490 3 0.33 0.60 0.34 0.0094 0.057
Ggamma8 L35921 2 0.74 0.58 0.33 0.0151 0.011
Rab-3b Y14019 3 1.39 -0.57 -0.32 0.0313 0.100
PDGF-associated protein U41744 2 -0.75 -0.61 -0.35 0.0046 0.004
proteasome component C3 J02897 2 -0.85 -0.81 -0.43 0.0025 0.002
MT versus Control 
CD68 antigen D64050 2 0.66 -0.52 -0.3 0.04 0.027
CBPTP M94043 2 1.92 -0.66 -0.36 0.0542 0.044
Rab-related GTP-binding M12481 2 2.03 0.63 0.35 0.0274 0.021
 
A more detailed analysis of the intra-assay correlation revealed remarkable differences 
between the individual experiments (figure 32) 
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Figure 32. Correlation of the expression profiles of individual MCT-treated samples. The 
diagrams show the adjusted differences (D values) of the experiments compared. (A) #1 versus 
#2, (B) #1 versus #4, (C) #2 versus #3, and (D) #3 versus #4. 
This inferior correlation can be due to biological and experimental variation. Interes-
tingly, only the expression profiles from the experiments #2 and #3 exhibits a weak 
correlation (figure 32 C). Exactly these two experiments have been conducted in 
parallel by the same experimenter (the animals were prepared at the same day from 
the same person), whereas all other animals were prepared at different days from 
different experimenters. This demonstrates a major contribution of experimental 
variation to the overall variation and, hence, the necessity of a parallel sample 
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preparation. But even the expression profiles of samples prepared in parallel only 
correlate weakly (R² ≅ 0.3), indicating considerable individual variations and limiting the 
power of a statistical analysis to identify differentially expressed genes. The power of a 
two-sided t-test to find a strong effect (observed value divided by the standard error > 
1) is estimated in the experiment in question to be smaller than 10% (calculated with 
Gpower®).86 The standard error can be reduced (and the power increased) by 
averaging more samples. 
5.2.1.2 Expression Profiles on Glass Slides  
The experiences from the nylon filter array experiments were considered for the 
experimental design using 10K oligonucleotide spotted glass arrays. All samples were 
prepared from the same person and whenever possible processed in parallel. 
Additionally, the number of individuals was considerably increased. For a power of 
90% to identify genes that are regulated by more than 2-fold, the number of samples 
was calculated to be greater than 16 (Gpower®, the standard deviation of the M values 
was estimated to be ~ 0.5). 
Three groups (i.e. MCT, MT, and Tola) with 6 individual per group were hybridized 
together with the control group (6 individuals) on rat 10K glass slides. A technical 
repetition of the hybridization was performed including a dye-swap to eliminate effects 
of any sequence-specific dye-bias. Figure 33 shows representative parts of the two 
scans of a dye-swap experiment. 
 
Figure 33. Dye swap on rat 10K oligonucleotide slides. (A) Slide where reference sample was 
labelled with Cy3 and treated sample with Cy5 while for dye swap approach (B) reference was 
(A) (B) 
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labelled with Cy5 and treated with Cy3. Blue rings are indicating how the color for spots in figure 
(A) and (B) switched in dye swap appraoch. 
The averaged results for each group are shown in figure 34. Clearly more genes were 
differentially regulated after treatment with MCT and MT than after Tolafentrine 
treatment. In all groups, more genes were found to be upregulated than genes to be 
downregulated. 
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Figure 34. A normalized MA-plot. Fits for the (A) MCT, (B) MT, and (C) Tola groups. 
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The probability of differential expression was estimated using the Bayesian approach 
with a fraction of 0.1% of the genes being differentially expressed. Genes were 
considered to be differentially expressed (selected) when the odds-ratio was greater 
than 10 (log odds >1) and the absolute log fold-change was greater than 1 (|M|>1). The 
distribution of the log odds and M values is illustrated in figure 35. 
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Figure 35. Volcano plots. (A) MCT, (B) MT, and (C) Tola. Selected genes are indicated by grey  
dots. 
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Figure 36 shows a comparison of the M values between the treatment groups to 
investigate the similarities and differences of gene regulation. 
 
 
 
 
 
 
Figure 36. Comparison of the M Values for Different Conditions. The compared conditions are 
given by the axis labels: Mono: MCT, Tola: tolafentrine, MT: MCT+Tola. Blue dots: similarly 
regulated in both conditions; red / green dots: regulated in one but not in the other condition. 
Genes that were found to be regulated in any of the three groups are listed in table 13. 
In total, 103, 54, and 25 genes were considered to be regulated, in the MCT, MT, and 
Tola groups, respectively.  
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Table 13. Differentially expressed genes in MCT, MT, and Tola groups.  
Growth factor/Cytokines/Chemokines 
Gene name MCT  MT  Tola GenBank 
accession  
Chemoattractant protein-1 1.2 - - NM_031530 
Bone morphogenetic protein type ii receptor - 2.0 - - AB073714 
Insulin-like growth factor binding protein 6 
Chemoattractant protein-1 
Chemokine c-x-c receptor 2 il8rb 
- 1.0 
1.2 
- 
- 1.1 
- 
- 
- 
- 
2.0 
NM_013104 
NM_031530 
NM_017183 
Transcription and Replication factors 
Gene name MCT  MT  Tola GenBank 
accession  
Topoisomerase dna ii alpha top2a 1.2 1.1 - NM_022183 
Hypoxia inducible factor 2 alpha hif-2a - 1.2 - - NM_023090 
Transcription factor fkhr - 1.1 - - AF247812 
Immunoglobin proteins 
Gene name MCT  MT  Tola GenBank 
accession  
Immunoglobulin light chain 2.1 1.7 1.1 M87786 
Immunoglobulin heavy chain variable region 1.6 - - AF217571 
Immunoglobulin kappa-chain igkv 2.1 1.1 - L07406 
t-cell receptor - 1.3 1.9 L20987 
Immunoglobulin gamma-2a chain 1.6 - - L22654 
  71
Signalling/ Transporter/ Receptor 
Serine / Aspartic proteases /Metalloproteinases/ Metabolic enzymes 
Gene name MCT  MT  Tola GenBank 
accession  
Serine protease      1.5 1.8 - D88250 
Secretory leukocyte protease inhibitor 1.5 
 
 
 
 
1.7 2.1 NM_053372 
Convertase pc5 - 1.2 1.2 L14933 
Alcohol dehydrogenase 3 adh3 - 1.1 - NM_019286 
Protease ii prt - 3.1 - J02712 
Mast-cell protease 5 precursor 
Mast-cell carboxypeptidase a precursor r-cpa 
Mast-cell protease 1 precursor rmcp-1 
Mast-cell protease 7 rmcp-7 
Mast-cell protease 8 precursor rmcp-8 
Rat mast-cell tryptase precursor 
Cathepsin K 
Cathepsin y 
4.2 
4.1 
4.2 
4.0 
3.5 
3.4 
1.9 
1.2 
- 
4.3 
4.0 
3.2 
3.4 
1.9 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
NM_013092 
U67914 
U67915 
NM_019322 
NM_019323 
NM_019180 
NM_031560 
AB023781 
Gene name MCT  MT  Tola GenBank 
accession  
Sodium/potassium-transporting gamma chain; 1.2 - - NM_017349 
Serine-threonine kinase receptor type i - 1.7 - - NM_022441 
Protein kinase c epsilon subspecies - 1.4 - - M18331 
Interleukin 1 receptor-1 fos-responsive gene  
Interleukin 1 receptor; type ii 
1.3 
- 
- 
1.7 
- 
2.3 
NM_013037 
NM_053953 
Melanocortin 5 receptor 
t-cell receptor 
Interleukin-3 receptor beta-subunit 
Calcitonin receptor-like receptor 
Adenosine deaminase 
Fit-1m fit-1 
Cell division cycle control protein 2 cdc2a 
Inositol hexakisphosphate kinase 
Equilbrative nitrobenzylthioinosine-sensitive  
Putative g protein coupled receptor g10d 
Ephrin b1 efnb1 
3’;5’-cyclic amp phosphodiesterase pde3 
- 
- 
1.2 
- 1.1 
1.2 
1.6 
1.2 
- 1.1 
- 1.2 
-1.4 
- 1.3 
- 
1.2 
1.3 
1.2 
- 
1.2 
1.1 
1.5 
- 
- 1.1 
- 1.0 
- 
1.4 
1.0 
1.8 
1.2 
- 
- 
- 
- 
- 
- 
- 
- 
2.5 
NM_013182 
L20987 
AJ000555 
NM_012717 
AB059655 
U04317 
NM_019296 
AB049151 
NM_031684 
NM_053302 
NM_017089 
U01280 
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Cathepsin s precursor 
Cytochrom c oxidase subunit viii-h heart/muscle 
cox8h 
Angiotensin i-converting enzyme dipeptidyl 
carboxypeptidase 1 
Matrix metalloproteinase 9 gelatinase b 
Tissue inhibitor of metalloproteinase 1 timp1 
Metallothionein 2 
1.4 
- 1.6 
 
- 1.2 
 
- 
1.6 
2.5 
1.2 
- 
 
- 
 
- 
- 
- 
- 
- 
 
- 
 
1.1 
- 
- 
NM_017320 
NM_012786 
 
NM_012544 
 
NM_031055 
NM_053819 
M11794 
Other proteins 
Gene name MCT  MT  Tola GenBank 
accession  
Apolipoprotein e rapoe 1.4 1.4 - S76779 
s100 calcium-binding protein a9 - 1.5 2.5 NM_053587 
s100 calcium-binding protein a8 - 1.5 2.7 NM_053822 
Arachidonate 5-lipoxygenase 1.0 - - NM_012822 
 
Several proteases, transporters, signalling, and immunoglobin proteins were regulated 
after MCT treatment. The additional application of tolafentrine (MT group) resulted in a 
reduced number of regulated genes, mainly growth factors, chemokines, and 
transcription factors (e.g., bmp2r, fkhr, il8rb). The regulation of most of the genes 
involved in inflammatory processes was not influenced by tolafentrine, whereas several 
genes were upregulated after tolafentrine (Tola) treatment (e.g., Il1Rii, Melanocortin 5 
receptor, t-cell receptor, pc5, adh3, prt ii, s100a9, and s100a8). 
5.2.2 Pneumolysin Induced Pulmonary Hypertension 
To differentiate the local effect of PLY to the lung epithelium that covers the airways 
and constitutes the first border of innate defense against respiratory pathogens from its 
systemic effects we applied either the PLY toxin intratracheally (IT) or via the systemic 
i.e. intravenously (IV). Interestingly, while systemic application resulted in healthy 
animals similar to the untreated control group, the intratracheal application led to sever 
illness, respiratory distress and death of the mice. The lungs showed a remarkable 
increase in weight by development of an edema. Additionally, in an ex-vivo model of a 
ventilated and perfused mouse lung (established in the group of PD Dr. N. Weissmann, 
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Internal Medicine-II) a significant increase in pulmonary artery pressure (PAP) could be 
measured (figure 37). Using this observation as a template we investigated the gene 
expression regulation in the organ model and animal model.  
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Figure 37. Effect of PLY in mouse lungs. PLY-toxin applied via IV and IT modes shows, 
increases in lungs weight (A) and PAP (B) via IT mode whereas, via IV mode there was no 
such changes. (Picture was adopted from N. Weissmann). 
5.2.2.1 Expression Profiles on Affymetrix Arrays 
Affymetrix arrays were applied to investigate the expression profiles in mouse lungs of 
mice treated with PLY via IT or via the IV. The lungs were obtained either from animal 
(in-vivo) or from organ (ex-vivo) ventilated and perfused lungs models. Total RNA was 
extracted from in-vivo and ex-vivo models as described in section 4.1.1. Applying 15 μg 
total RNA and one round of T7-linear preamplification, 40-50 μg labelled cRNA were 
generated. Figure 38 shows a representative electropherogram of the cRNA used for 
the hybridizations. 
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Figure 38. Electropherogram of cRNA. Electropherogram of cRNA obtained after one round of 
T7-IVT. RFU: relative fluorescence units. 
5.2.2.2 PLY-Dependent Gene Expression in the Animal Model (in-vivo) 
15 μg labelled and fragmented cRNA were hybridized to Affymetrix® GeneChip® 
U74Av2 arrays at the Max-von-Petemkofer Institute, Ludwig-Maximilian-University of 
Munich, Germany. Hierarchical cluster analyses were performed using dChip to 
examine the similarity of the expression patterns between the treatment groups and the 
controls. The results of the cluster analyses are show in figure 39. 
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Figure 39. Hierarchical clustering. (A) With row and column standardization. (B) Without 
standardization. Distance measure and linkage type are given in the figure. The arrows indicate 
possible mixes of samples (see text). 
The cluster analysis did not separate any of the treatment groups. A possible reason 
could be mixed-up samples. Using the standardized data, one has to assume the mix-
up of at least three samples to get two major clusters clearly separating the IT treated 
samples (figure 39 a). Without standardization, the clusters seem to be more 
reasonable with a better separation of the IT group, and a perfect separation after 
exchanging only two of the samples (i.e., 04_Control 2 and 08_IT 3, fig 39 b). The 
connection of the clusters, including the propably interchanged samples, was robust 
with respect to the way the distance matrix and the linkage are calculated.  
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To confirm the interchange of the two samples, an additional control sample was 
measured and included in the cluster analysis (figure 40). 
 
Figure 40. Hierarchical clustering with an additional control sample. Distance measure and 
linkage type are given in the figure. A frame indicates the additional control sample. 
The additional control sample (07_Control_A) clusters next to 08_IT 3 which is 
suspected to be the other control sample, 04_Control 2. This result strongly supports 
the hypothesis that the samples 04_Control 2 and 08_IT 3 were mixed-up. 
Consequently, for the further analysis 04_Control 2 was assigned to be 08_IT 3 and 
vice versa. The corrected clusters show a perfect separation of the IT samples from the 
IV samples and from the controls, whereas there is only a very week separation 
between the IV’s and the controls. Since there is no significant difference between the 
expression profiles of IV’s and controls, the IV’s were used as reference for calculating 
the differential expression of the IT samples. 
The data obtained from PLY response via IT revealed 280 upregulated and 30 
downregulated genes by more than a factor of 2. (see table I4). 
Table 14. Differentially expressed genes after PLY treatment in the animal model. The log fold 
changes between the conditions compared are shown. 
Probe ID Gene Name IT1/IV1 IT2/IV2 IT3/IV3 
96192_at Trans-acting transcription factor 3 3.48 2.45 5.17 
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Probe ID Gene Name IT1/IV1 IT2/IV2 IT3/IV3 
104407_at Activated leukocyte cell adhesion molecule 3.45 2.68 4.63 
92579_at Sjogren syndrome antigen B 3.42 2.58 4.93 
98572_at DnaJ (Hsp40) homolog, subfamily B, member 11 3.23 2,26 4.96 
102906_at T-cell specific GTPase 3.23 2.02 4.65 
161184_f_at Tyrosine kinase receptor 1 3.23 2.24 5.01 
94939_at CD53 antigen 3.04 2.39 4.14 
98472_at Histocompatibility 2, T region locus 23 3.04 2.19 4.68 
161224_f_at Angiotensin converting enzyme 3.04 2.31 4.29 
161104_at Expressed sequecnce AA408298 3.08 2.53 3.7 
92647_at Retinoblastoma binding protein 4 3.02 2.28 4.35 
95120_at RIKEN cDNA 1100001I23 gene 3.02 2.11 4.53 
99643_f_at Carboxypeptidase E 3.02 2.06 4.69 
102904_at Histocompatibility 2, class II antigen E alpha 3.02 2.15 4.8 
92660_f_at Ubiquitin-conjugating enzyme E2E 1,  2.96 2.15 4.97 
96012_f_at Matrin 3 2.95 2.16 4.46 
99532_at Transducer of ErbB-2.1 2.95 2.19 4.28 
92291_f_at Complement factor H-related protein 2.95 2.03 4.92 
96852_at cAMP dependent regulatory Protein kinase 
type I, alpha 
2.91 2.07 4.59 
93104_at B-cell translocation gene 1, anti-proliferative 2.90 2.14 4.24 
93351_at Hydroxyprostaglandin dehydrogenase 15 (NAD) 2.89 2.00 4.93 
160643_at Histone deacetylase  2.88 2.22 3.91 
100032_at Trans-acting transcription factor 1 2.86 2.32 3.53 
100344_at CD2-associated protein - 2.28 - 2.01 - 2.61 
93908_f_at Carbon catabolite repression 4 homolog  
(S. cerevisiae) 
- 2.45 - 2.05 - 2.96 
161341_f_at GA repeat binding protein, beta 1 - 2.48 -.2.07 - 3.00 
92306_at Ovary testis transcribed - 2.61 - 2.02 - 3.29 
100914_at CD84 antigen - 2.63 - 2.19 - 3.12 
100721_f_at Recombinant antineuraminidase single chain Ig VH 
and VL domains 
- 2.72 - 2.07 - 3.85 
101732_at Per-hexamer repeat gene 5 - 3.04 - 2.34 - 3.82 
98772_at Small inducible cytokine B subfamily, member 5 - 3.14 - 2.36 - 4.46 
97127_f_at Vomeronasal 2, receptor, 15 - 3.25 - 2.72 - 3.89 
100687_f_at Vomeronasal 2, receptor, 14 - 3.39 - 2.46 -4 .15 
98524_f_at RIKEN cDNA 2210039B01 gene - 3.39 - 2.46 - 4.41 
94028_f_at CD84 antigen - 3.94 - 2.74 - 5.53 
103269_f_at Zinc finger protein 125 - 4.07 - 3.00 - 5.43 
98577_f_at Endogenous retroviral sequence 4 - 4.28 - 2.94 - 7.50 
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Probe ID Gene Name IT1/IV1 IT2/IV2 IT3/IV3 
103267_i_at Zinc finger protein 125 - 4.60 - 3.56 -6.08 
160934_s_at Intracisternal A particles - 5.30 - 4.52 - 6.22 
160906_i_at RIKEN cDNA 2210039B01 gene - 7.72 - 4.52 - 11.4 
100920_at RIKEN cDNA 2210039B01 gene - 8.12 - 5.34 -14.5 
102818_at Xlr-related, meiosis regulated - 8.20 - 4.41 - 26.0 
 
5.2.2.3 PLY-Dependent Gene Expression in the organ model (ex-vivo) 
The genes found to be regulated by more than a factor of 2 in the ex-vivo PLY treated 
lungs are listed in table 15.  
Table 15. Differentially Expressed Genes after PLY Treatment in the ex-vivo Model. The log 
fold changes between the conditions compared are shown. 
Probe ID Gene Name log fold-
change 
IT versus IT C 
100593_at Troponin T2, cardiac 2.93 
101071_at Myosin heavy chain, cardiac muscle, adult 2.70 
101028_i_at Actin, alpha, cardiac 2.48 
100921_at Troponin I, cardiac 2.40 
160487_at Myosin light chain, alkali, cardiac atria 2.21 
93534_at Decorin 1.84 
160242_at Expressed sequence AU014660 1.76 
98049_at RIKEN cDNA 1300018I05 gene 1.70 
103349_at Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 1.89 
93617_at Chemokine (C-C) receptor 1,-like 2 -1.98 
97740_at RIKEN cDNA 3830417M17 gene -2.04 
93869_s_at B-cell leukemia/lymphoma 2 related protein A1d -2.17 
102658_at Interleukin 1 receptor, type II -2.54 
161689_f_at Interleukin 1 receptor, type II -2.87 
98423_at Gap junction membrane channel protein beta 2 -3.17 
93858_at Small inducible cytokine B subfamily (Cys-X-Cys), member 10 -3.31 
IV versus IV C 
96875_r_at RIKEN cDNA 1200003J11 gene 2.16 
104046_at Expressed sequence AU021774 2.10 
92569_f_at Nucleolar protein 5 2.01 
102197_at Nucleobindin 2 1.97 
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Probe ID Gene Name log fold-
change 
104340_at Methyl-CpG binding domain protein 1 1.96 
98465_f_at Interferon activated gene 204 1.96 
97205_at Expressed sequence AA409117 1.91 
99535_at Carbon catabolite repression 4 homolog (S. cerevisiae) 1.91 
93316_at cDNA sequence AB017026 1.90 
96041_at RNA binding motif protein 3 1.86 
161980_f_at Bcl2-associated athanogene  1.84 
95518_at RIKEN cDNA 1810015C04 gene 1.82 
92789_r_at centrin 3 1.81 
93430_at chemokine orphan receptor 1 1.80 
104419_at DNA segment, Chr 14, ERATO Doi 453, expressed 1.79 
103015_at B-cell leukemia/lymphoma 6 1.71 
99031_at Expressed sequence AA407558 1.71 
92660_f_at ubiquitin-conjugating enzyme E2E 1, UBC4/5 homolog (yeast) 1.71 
94939_at CD53 antigen 1.69 
96238_at RAB11a, member RAS oncogene family 1.69 
161104_at Expressed sequence AA408298 1.68 
95516_at RAB9, member RAS oncogene family 1.67 
99582_at Tumor-associated calcium signal transducer  1.67 
99462_at Topoisomerase (DNA) II beta 1.65 
103275_at ATPase, H+ transporting, lysosomal (vacuolar proton pump) 
noncatalytic accessory protein 1A (110/160 kDa) 
-1.80 
102698_at Endothelial PAS domain protein 1 -3.40 
5.2.2.4 Intersection of the results found in the in-vivo and ex-vivo models 
An intersection of the results between in-vivo (IT/IV) and ex-vivo (IT/IT-control) models 
was made to understand the similarities between them. Genes that were showing 
similar regulation pattern in in-vivo model (IT/IT-control) and ex-vivo model (IV/IV-
control) are shown below:  
Topoisomerase II beta 
R- cDNA 18100115C04 
R-cDNA C330007P06 gene 
Sjogren syndrom antigenB 
Bcl2-athanigene 3 
CD53 antigen 
R-cDNA 231000F16 gene 
MAC kinase 1 
Centrin 3 
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Phosphofructokinase, platelet 
RA11a, member RAS oncogene family 
Expressed sequence AA409117 
Expressed sequence U13839 
Syndecan binding protein 
RAB9, member RAS oncogene family 
Laminin B1 subunit 1 
No genes were found to show similar regulation patterns in the in-vivo model (IT/IT-
control) and in the ex-vivo model (IT/IT-control).  
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6 Discussion  
6.1 Microarray technology 
Microarray analysis is a very powerful technique that can provide important 
information. It is necessary to validate all data obtained through microarray analysis. 
Microarrays can provide information on global gene expression in an organism, tissue, 
or cell. Unfortunately, microarray technology is not a simple technique in practice. To 
establish the application of microarray technology in the laboratory, many technical 
parameters and methods need to be optimized to minimize technical errors associated 
with microarray studies. In particular, RNA extraction, preamplification, labelling, as 
well as the complete slide handling including pre-processing, hybridization, washing 
and drying have to be optimized carefully in order to obtain best possible results.  
6.1.1 RNA Isolation and Labelling 
The major factor that determines the quality of the microarray experiment is the quality 
of the sample RNA used. Since RNA quality and quantity is the most critical 
checkpoints to perform microarray experiments, three different known methods for 
RNA extraction were tested. The combination of RNA extraction by Trifast and the 
purification employing an RNeasy column including a DNase treatment was most 
productive (100 µg RNA / 60 mg tissue and yielded pure nucleic acids (OD260/OD280 ≥ 
1.8).  
To investigate the expression profiles, the extracted and purified RNA sample has to 
be labelled, i.e., labelled cDNA or aRNA have to be made using the isolated RNA as 
template. The cDNA can either be labelled directly by introducing Cy-labelled 
deoxynucleotides during the reverse transcription or indirectly by introducing 
aminoallylated deoxynucleotides that are subsequently coupled to free reactive dye 
molecules. It is essential to generate sufficient amounts of labelled products to get 
  82
detectable signals for all present sequences. The presently available laser powers and 
sensitivities of the detection systems yield optimal results when more than 20 pmol 
CyDyes are hybridized. The dye molecules attached to the cDNA should be separated 
by an average of 100-200 nucleotides, what corresponds to a frequency of 
incorporation (FOI) of 5-10 CyDyes / kb. Lower FOIs make more cDNA necessary to 
get sufficient fluorescence signals. It can be problematic to get enough cDNA for low 
FOIs. Additionally, the absolute amount of cDNA required for sufficient signals might 
then be so high that the spotted probes get saturated. It is not yet solved if and how the 
fluorescence signals can be normalized, i.e., corrected for intensity-dependent 
artefacts, when a considerable fraction of the spots is saturated. In this case, some of 
the ratios would be the result of the total abundance of labelled target sequences, 
whereas others would be the result of an actually competitive hybridization and directly 
reflect the relative amounts of two samples. On the other hand, higher FOIs result in a 
steric hindrance during hybridization and to a loss of signal due to intermolecular 
energy transfer between the fluorophors. 
The results presented in 5.1.3 suggest that it is much more likely to get relatively low 
FOIs. The FOI for indirectly labelled cDNA is expected to be the highest among the 
tested methods, because the amino-modified deoxynucleotides are much smaller than 
the comparably bulky CyDye-conjugates and thus are incorporated with a higher 
fidelity by the enzyme. Additionally, the aminoallylation is performed for three PCR 
cycles, enhancing the yield. However, the comparison of the amounts of generated 
cDNA reveals that the repetitive aminoallylation is the major factor for increased 
amounts of labelled products: whereas the FOI of the indirectly labelled products was 
only slightly higher than that of the directly labelled products (11 vs. 7.5), the total 
amount of incorporated dyes was more than eight times higher. Corrected for the FOI 
follows a total yield of about 8 nmol (2.5 nmol) cDNA for the indirectly (directly) labelled 
product. This demonstrates that the efficiency of the aminoallylation-PCR was 
considerably lower than 2 (~1.5), indicating some disturbing influence of the allylated 
deoxynucleotides. For oligonucleotide-spotted arrays, the effective difference between 
the two methods is less pronounced as indicated by the presented values, because 
only half of the indirectly labelled double-stranded cDNA can actually hybridize to the 
spotted sequences. 
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Furthermore, the results in 5.1.2 demonstrate that there are differences in the fidelities 
of different reverse transcriptases to incorporate Cy-labelled nucleotides, too. 
SuperScript II was more efficient and more productive (30 pmol) than OminiScript, 
followed by FluoroScript and CyScribe.  
6.1.2 Hybridization and Washing 
The quality of the scanned images has a major impact on the value of the results. A 
predominant problem during this work concerning the image quality was extraordinary 
high background fluorescence on the slides. This background was observed mainly as 
a "green" smear more or less equally distributed over the slides, but also as "red" rings 
around the spots (figure 18).  
First, the red rings are likely to be a property of the slides itself. This is supported by 
the fact that they were observed exclusively on the cDNA-spotted slides obtained from 
the DKFZ. It is possible that these fluorescing structures are caused by a suboptimal 
composition of the spotting buffer and/or by suboptimal spotting conditions, e.g., by an 
inadequate humidity in the spotting chamber. It was not possible to remove these 
artefacts with extensive washing of the slides. A proper evaluation of such slides is not 
well possible, because the spot-finding algorithms are unable to identify spots 
surrounded by excessive fluorescence. Additionally, a local background correction 
would result in negative values when the intensity of the ring structures is higher than 
those of the spots. 
Secondly, the green smear can have many different sources, so that the identification 
of the actual origin may be quite difficult. The most prominent sources for background 
fluorescence are dyes or labelled non-hybridized products remaining on the slide after 
insufficient washing. Alternatively, SDS as part of many washing buffers may remain 
on the slides and thus add to the background fluorescence.  
Remaining dyes would give measurable background signals in both channels. This 
was not observed during the works. It is thus unlikely that insufficient washing was the 
reason for the observed high background. SDS was also implausible since the whole 
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amount of SDS in the wash buffers is not able to cause such high fluorescence as 
observed (figure 18 a). 
 
To select a reliable set of series of wash buffers (i.e. initially with low-stringency wash 
buffer, then with high-stringency wash buffer, and finally with post-wash buffer), we 
have tested three different series of set of wash buffers on cDNA spotted slides from 
DKFZ and oligospotted slides from MWG. Our buffer tests show that test 3 (as 
described in 5.1.4.1) on DKFZ and MWG slides did not show green fluorescency while 
the other two tests i.e. test 1 and test 2 (as described in 5.1.4.1) showed fluorescency. 
This tests suggests us to use only a third set of buffers i.e. initially with low-stringency 
wash buffer 2XSSC; 0.2%SDS, then with high-stringency wash buffer (1X SSC), and 
finally with post-wash buffer (0.5% SSC). 
Ethanol has also been discussed as a source of unspecific fluorescence.81 This finding 
can be supported by the results of this work (see figure 19). It is a source of direct 
contamination of the slides that need to be preprocessed with ethanol, but additionally 
indirectly by the manifold and the slide covers of the hybridization station that are 
intensively washed with ethanol.  
Unfortunately, the background fluorescence could not be eliminated by changing the 
ethanol brand, indicating a further source of the contaminations. Following the hints of 
personal communications with the members of the DKFZ, also the canned air used to 
dry the slides was tested. It turned out that the canned air itself does not seem to 
contain any fluorescent particles. Not any fluorescence was measured on dry slides 
that have been intensively sprayed with canned air. However, using wet slides, 
significant background signal was detected (figure 20). Again, it took another round of 
investigation until it became clear that the manifold – also dried with canned air– 
accumulates fluorescing particles that are flushed over the slides during the machine 
washing (figure 21). 
Finally, oligonucleotide arrays appear to have some important advantages over cDNA 
arrays. In particular, specific, highly unique sequences can be selected for each gene 
and thus cross-hybridization can be minimized. Furthermore, most of the cDNAs in the 
cDNA libraries are insufficiently annotated. Apart from these advantages, 
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oligonucleotide-spotted arrays exhibit superior spot morphologies. This is 
demonstrated in 5.1.5. All key parameters of the slide quality, i.e signal-to-noise ratio 
foreground-to-background ratio, and spot morphology were clearly better for the 
oligonucleotide spotted arrays than for the cDNA spotted arrays.  
6.1.3 RNA Preamplification 
Amplification strategies represent the most promising approach currently being 
pursued to reduce the microgram quantities of RNA required to perform single 
microarray hybridization. At present, the most commonly used amplification methods 
are (i) linear amplification by In-vitro transcription (IVT) and (ii) PCR based exponential 
amplification with a switching mechanism at the 5' end of the RNA transcript (SMART). 
Here, the performances of both methods were compared. Although both methods have 
been tested for reliability and suitability,87 a fair and direct comparison of both methods 
has not yet been published. Recently, a comprehensive comparison study for the 
expression profiling using one microgram of total RNA for IVT (one round) and SMART 
have been reported by M. Saghizadeh et al. They showed that the relative abundance 
of RNA species in the amplified probes (IVT and SMART) is highly maintained during 
the amplification process, independent of the method.87 However, 1 µg total RNA is still 
hard to obtain from small biopsies of laser microdissected cells. Thus 50 ng total RNA 
were used in this work, which is 20 times less then used by M. Saghizadeh et al. Since 
one round of IVT does not yield enough product for a satisfactory hybridization from 
this little amount of starting material, two subsequent rounds IVT were performed.  
The process of IVT preferably amplifies sequences close to the poly-A tail of the 
mRNAs.88 This effect is responsible for the lower average length of aRNA compared to 
that of the mRNA. Although this fact has no significant influence on the outcome of 
microarray experiments when only one round is performed, it is likely that this may 
result in an accumulation of drastically shortened products after two subsequent 
rounds of IVT. These short products may lack the parts of the sequence 
complementary to the spotted probes. In contrast to the IVT, SMART is said to amplify 
full-length products avoiding the problems arising from poly-A biased products.89 On 
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the other hand the exponential amplification possess the potential to amplify small 
initial errors and hence to alter the underlying transcription profile.  
The results presented in 5.1.6.1 demonstrate that two rounds of IVT do in deed result 
in a strongly biased amplification of sequences close to the poly-A tail, whereas 
SMART amplifies all sequences equally well. After 2 rounds of IVT, the highest ΔCt 
values observed were about 10, that corresponds to a 210 ≈ 1000-fold overall 
amplification (GAPDH-3’UTR). The tested sequence of PBGD with a distance of 
1400 bp to the poly-A tail revealed an amplification factor of just 5. The observed 
reduction of the amplification factors corresponds well with the ratios of 3’-to-5’-signals 
reported for affymetrix arrays.90 These results demonstrate the ability of SMART to 
amplify longer products than T7-IVT.  
It is reported that one round of IVT yields up to  ~2 µg aRNA from 100 ng total RNA.91 
Under the assumption that about 1- 5% of total RNA are polyA RNAs, this corresponds 
to a 400 - 1000-fold amplification. After two rounds of IVT starting with 50 ng total RNA 
about 50 µg aRNA were obtained, corresponding to a 2·104 – 105-fold amplification of 
the polyA RNAs. This yield is marginally less than theoretically expected (~106), that 
could be explained by the fact that Cy-labeled ribonucleotides had to be incorporated in 
the second round of IVT likely reducing the efficiency of the RNA polymerase. 
Additionally, a loss-prone purification step had to be performed. Interestingly, the 
amplification factors of specific target sequences as determined by real-time PCR were 
considerably lower. The reason for this discrepancy remains unclear, but the 
amplification of non-polyA RNA may serve as a possible hypothesis. 
The amplification factors obtained by 12 cycles SMART are already higher than those 
obtained by 2 rounds of IVT, and they still can be further increased by performing more 
PCR cycles. After 24 cycles of SMART, the ideal efficiency of amplification is not 
reached. Instead of a shift of the Ct values by 24, the shift observed was only 18. This 
can be attributed to the fact that the reaction ran into to plateau phase. Because the 
amplification processes become unpredictable when the accumulation of products 
starts to plateau, it must be taken care that PCR cycles have to be stopped in time. 
When the amount of starting material is not known, the optimum number of cycles 
yielding as much product as possible without running into the plateau phase should be 
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empirically determined. This can be done according to the procedure described in 
SMART Fluorescent Probe Amplification kit manual: after each (two) cycle(s), an 
aliquot of the SMART reaction can be introduced to a real-time PCR. Plotting the Ct 
values versus the numbers of SMART cycles will reveal a negative linear trend until the 
point where the SMART reaction started to plateau.  
How accurately the transcription profiles were maintained by the amplification methods 
was analysed in microarray experiments. Here, aliquots of RNA from mouse liver and 
kidney were subjected to a direct labelling as well as to preamplification and labelling 
by 2 rounds IVT and by 15 cycles SMART. The direct comparisons of the M values 
from two independent replicates demonstrate a very bad correlation of profiles after 
IVT (figure 26). This extreme result is unexpected since the linear amplification should 
yield more constant or reliable results than the exponential amplification. To elucidate 
whether this low correlation was due to experimental errors, more repetitions would 
have to be performed. Anyway, these results show that two rounds of IVT hold a high 
risk of low reproducibility. 
As already expected from the inferior correlation of technical repeats, the averaged 
profiles of the IVT amplified samples correlated only weakly with those of the 
unamplified reference (figure 27). In contrast, the SMART amplified samples correlated 
noticeably better with the reference (figure 27). Both comparisons show that the M 
values of the preamplified samples are compressed relative to the reference. This 
phenomenon is also reported by others.90-91 
Another important property to address is the accuracy of the results. This point is 
difficult to assess and frequently not even touched in the respective publications. 
Ideally, samples with known expression profiles would be required to estimate the 
accuracy of microarray experiments, but such information is not (yet) available. At least 
parts of this information are increasingly more collected in expression databases. The 
comparison of the lists of differentially expressed genes between liver and kidney with 
the results presented in the databases showed that the number of false positives is low 
for all samples (figure 29, right one). The false-positive rate was low even for the IVT 
amplified samples, although the two individual experiments had a bad correlation / high 
variance. This high degree of correctly selected genes may be attributed to the robust 
Bayesian algorithm of candidate selection. Notably, the list obtained from the SMART 
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amplified samples was not only larger, but also contained more correct genes than the 
list of the unamplified reference sample (figure 29, right one). That fact that more 
genes were selected can be explained by the lower inter-assay variance of the SMART 
samples. Again, this might be a general effect of the SMART reaction itself or just the 
result of lucky circumstances. To comprehensively evaluate this aspect, considerably 
more repetitions have to be done. 
In conclusion, SMART turned out to be the preferred technique to amplify very small 
amounts of RNA. It was more reliable, precise, and accurate and considerably less 
time-consuming than two rounds IVT. Moreover, in contrast to IVT that produces 
relatively unstable aRNA, SMART yields labelled cDNA that is less prone to 
degradation by prolonged storage and repeated freezing/thawing cycles.  
6.2 MCT-Dependent Gene Expression 
6.2.1 Differences between Nylon- and Glass-Arrays 
Microarray technology permits the analysis of the gene expression profile of rats lung 
tissue obtained from MCT-induced and Tola-attenuated PH to compare to that found in 
normal lung tissue. In this rat model, the subcutaneouslly applied monocrotaline (an 
alkaloid toxin) induces on the basis of inflammation changes in the structure and 
function of endothelial cells, smooth muscle cells, and fibroblasts contributing to the 
vascular remodelling, altered tone, and vasoreactivity that are characteristics of chronic 
pulmonary hypertension.92-93.  
For the expression profiling study we used small pieces of lung tissue samples keeping 
in consideration that these samples are representative for the entire lung. Starting with 
nylon filters and 1,176 spotted cDNAs, we investigated the expression profile of MCT-
induced and Tola-attenuated PH in rats.  
In MCT group, out of 703 evaluated genes, 11 genes were selected. Among the 
selected genes, one of the most upregulated genes was Gamma-aminobutyric acid 
(GABA) receptor alpha 1. GABA is an important inhibitory neurotransmitter in the 
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mammalian CNS and also found in peripheral tissues, including the lung. It has 
recently been shown to modulate the contraction of airway smooth muscle.94 Thus, it 
has to be evaluated now which compartment has caused the regulation of this 
receptor.  
Alkaline phosphatase (ALP) was also found to be upregulated. In lung lavage fluids, an 
increased level of ALP is a marker for tissue damage and type II cell proliferation. Type 
II pneumocytes are extensively involved in the inflammatory process within the alveolar 
septum that may explain the upregulation. Moreover, an increase of the ALP: albumin 
ratio in bronchoalveolar lavage fluids from patients with chronic interstitial disorders 
may reflect a fibrosing progression.95 
Alterations in the levels of the growth factor transcripts such as Platelet-derived growth 
factor (PDGF)-associated protein may have a significant role in the development of 
pulmonary hypertensive disease. PDGF-associated protein has been implicated in 
myointimal proliferative arteriopathy, a lesion seen in monocrotaline-induced 
pulmonary hypertension. Arcot SS et al. showed that transcripts of PDGF were 
increased in the early stages but declined in the later stages of MCT-induced 
hypertension.96 Well in line with this finding we found the PDGF associated protein 
downregulated after 4 weeks as well. 
Additionally, rac-alpha serine/ threonine kinase and Rab-3b ras-related protein, two 
members of the group of oncogenes and tumour suppressor proteins, were found to be 
downregulated indicating changes in the proliferation rate and induction of apoptosis.  
However, the most important result of the approach with nylon filters is the weak or 
even absent correlation of the single experiments. Obviously, preparation of animals by 
different experimenters at different time points contributed in a way to the overall 
variation that it may almost completely prevent a reasonable statistical analysis. Only 
the expression profiles from the experiments #2 and #3 exhibit a weak correlation 
(figure 32 C). Exactly these two experiments have been conducted in parallel by the 
same experimenter (the animals were prepared at the same day from the same 
person), whereas all other animals were prepared at different days from different 
experimenters. This demonstrates the necessity of strategical planning of the process 
of sample collection and the importance of a parallel sample preparation.  
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6.2.2 Effects of MCT Treatment 
Using oligonucleotides spotted glass chips, we characterized the expression pattern in 
the lung tissue obtained from the three different groups i.e. MCT, MCT+Tola (MT) and 
Tola alone to compare with that found in normal lung tissue. So far, less work has been 
performed in context to identified candidate genes that are involving in PH disease. 
Recently, Norbert F. Voelkel et al. investigated differentially regulated genes in PPH 
human samples.97 Here, for selecting differentially regulated genes in each groups, we 
applied a regulation criterion that is a twofold change in expression [log2 ratio of 1.0 
(upregulation) or -1.0 (downregulation)]. 
As the inflammatory mechanisms appear to play a significant role in MCT-PH model,36 
we hypothesized that factors such as inflammatory mediators, proteases and elastase, 
matrix metalloproteinase, ion channels, or vascular endothelial growth factors may 
have role in progression of the disease. We obtained 103 genes, which were regulating 
with a 2-foldchange. Few of them are discussed here.  
A link between MCT-induced inflammation and smooth muscle cell (SMC) proliferation 
was first suggested by certain findings in pulmonary hypertension. SMC proliferation 
has also been demonstrated in the pulmonary vasculature in chronic PH of animal 
models.98 Proinflammatory interleukins are intriguing candidates for a MCT-induced 
SMC-derived autocrine growth factor. As expected, pro-inflammatory genes like IL-3 
receptor beta and IL-1 receptor 1, excessively produced in the lungs of rats treated 
with monocrotaline,99 were upregulated here. Overexpressions of these cytokines 
stimulate proliferation of SMC. Such proliferation may contribute to the 
pathophysiological effects of chronic MCT induced PH and thus may play a role in the 
development of pulmonary hypertension.  
Overexpression of arachidonate 5-lipoxygenase and chemoattractant protein-1 (MCP-
1) was shown in endothelial cells of plexiform lesions and inflammatory cells in patients 
with PPH.100 Interestingly, these genes were upregulated with more than a factor of 2.0, 
suggesting that upregulation of these enzymes involved in generation of inflammatory 
mediators and may play a role in the pathogenesis of PH.   
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Mast cells are specialized immune effector cells that synthesize and store in their 
granules large amounts of serine proteases, marked, statistically significant increases 
in proteases (particularly derived from mast cells) of vascular obliteration and 
pulmonary hypertension. Mast-cell-derived proteases may play a role in regulating the 
development of neointimal pulmonary vascular occlusion and pulmonary hypertension 
in response to injury. Indicating involvement in the remodelling process, our array data 
show that several mast-cell-derived proteases like mast-cell protease 1, 5, 7 and 8 
precursors were highly upregulated by more than a factor of 5.0. Similar regulation 
pattern for mast cell proteases in MCT rat model was reported by Laszlo T et al.101 In 
addition to this, other proteases like serine protease was found to be upregulated. 
Increased activity of serine proteases in pulmonary arteries has been observed during 
early remodelling in MCT-induced pulmonary hypertension.102  
Besides mast cell proteases and serine proteases, some other proteases expression 
was found to be significantly elevated during the development of disease, for example, 
cathepsin K (3.0-fold) and cathepsin Y (approx. 2.0-fold) which has an influence on 
developing PH. Cathepsin K is a protease with potent fibrinolytic activity that may play 
an important role in extracellular matrix degradation. Again Laszlo T et al. showed 
upregulation of cathepsin K in MCT rat model.  
Important changes occur in PH in the vascular adventitia, with increased production of 
the extracellular matrix. Cowan et al. recently showed that direct inhibition of serine 
elastases led to complete regression of pathological changes in experimental PH 
caused by monocrotaline.103 Because metalloproteinases are potentially destructive 
agents, their production is tightly controlled at several levels. A way in which the activity 
of MMPs is regulated is based on the presence and activity of specific inhibitors such 
as TIMP-1,104-105 which was upregulated, such overexpression is due to the interaction 
of MMPs with their specific inhibitors that determines the net activity of secreted 
enzymes during pulmonary artery remodelling. Because our results showing that mast 
cell proteases, cathepsins, and TIMP are increased during progression of pulmonary 
hypertension that extends the observations that experimental pulmonary hypertension 
involves extensive remodelling of extracellular matrix. 103  
Upregulation of Insulin-like growth factor-1 IGF has been recognized as likely having a 
role in stimulating smooth muscle hyperplasia.106 IGF-I directly stimulate fibroblast 
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proliferation and perhaps collagen synthesis.107 We found upregulation of IGF, such 
overexpression of IGF-1 can leads to increased cell proliferation decreased apoptosis 
and increased smooth muscle elastin synthesis that may play an important role in 
vascular remodelling in chronic pulmonary hypertension.  
A member of the metal binding protein family is metallothionein 2 (MT-2), a low–
molecular weight, cysteine-rich, heavy metal-binding protein can be easily induced by 
heavy metals, hormones, acute stress, and various chemicals.108 In our approach, MT-
2 was upregulated. This enzyme might play a role in the pulmonary defense against 
zinc toxicity and free radicals. As MCT rat model is a chronic PH model it influences 
upregulation of MT-2 against toxicity and free radicals. Interestingly, upregulation of 
metallothionein 1 and 2 in pulmonary arteries were found in parallel during hypoxia 
induced pulmonary hypertension (unpublished data communicated by L. Fink). 
Furthermore, MT-2 previously has been shown to increase after an ischemic insult.109 
Flavin-containing monooxygenase 1 (FMO) is a member of xenobiotic-metabolizing 
enzymes family. In normal condition, FMO oxidatively metabolizes a wide variety of 
nitrogen-, sulfur-, and phosphorous-containing xenobiotics compounds. In our setting, 
downregulation of FMO indicates the increased deposition of toxic reactive 
intermediates that might involve in a vascular injury. 
On the other hand several genes were differentially downregulated in response to 
MCT. Among downregulated genes most of them are belongs to kinases family, for 
example; fms-related tyrosine kinase 1, protein kinase c, serine-threonine kinase 
receptor type I activin, and Inositol hexakisphosphate kinase (IP6) enzymes were found 
to be downreguled. Kinases have been shown in vascular smooth muscle cells to 
regulate the expression of p27KIP1 leading to an enhanced G1/S transition of vascular 
smooth muscle cells.110 A member of apoptosis regulation family i.e. IP6 in response to 
MCT was downregulated. Members of this family involved in apoptosis regulation.111 
Furthermore, IP6 is a naturally occurring polyphosphorylated carbohydrate that is 
present in substantial amounts in almost all mammalian cells, which are important for 
regulating vital cellular functions. It was recently recognized to possess multiple 
biological functions. A striking anticancer effect of IP6 was demonstrated in different 
experimental models IP6 is involved in apoptosis and vessel maintenance.112 
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Some receptors play a key role in angiogenesis. Ephrin b1 was downregulated and is 
known to be involved in vascular development and angiogenesis.113 Downregulation of 
ephrin b1 results in reduced vessels sprouting and development. 
Interestingly, the most downregulated gene in our approach is BMPR-II that is known 
to have an important role in PPH. Diverse mutations in BMPR-II receptor followed by 
functional loss of BMPR II have been reported in patients with PPH.114 BMPR2 
encodes a type II receptor member of the transforming growth factor-ß (TGF-ß) 
superfamily. Type II receptors have serine/threonine kinase activity and act as cell-
signallimg molecules. Following ligand binding, type II receptors form heterodimeric 
complexes with membrane-bound type I receptors. This initiates phosphorylation of the 
type I receptor and downstream signalling via intracellular Smads.115 This pathway is 
diverse and the specificity in cell growth and differentiation is mediated through 
transcriptional control. Thus, for the first time downregulation of BMPR2 was found in 
an animal model of PH.  
6.2.3 Effects of MCT attenuation with Tolafentrine 
For the MT group we hypothesized that some functionally related genes would be 
consistently and statistically significantly coexpressed during the development of 
disease and downregulated in response to treatment.  Our first hypothesis came out to 
be true and 33 genes found to be regulated in MCT group showed similar regulation 
pattern in the MT group as well. Among these genes, 28 (5) were up-(down-) 
regulated. Many of them belong to the mast cell proteases, proteases inhibitors (TIMP-
1), and immunoglobulin molecules. This similar regulation pattern in MCT and MT 
groups (typically seen for mast cell proteases) might have the reason that tolafentrine 
(a synthetic PDE 3/4 inhibitor) does not effect the structural matrix remodelling 
process. In continuation, Kohyama T et al. showed that out of three types of PDE4 
inhibitors (cilomilast, amrinone, and zaprinast), only cilomilast significantly inhibited the 
MMP-1 release and activation while neither amrinone nor zaprinast had any effect on 
collagen degradation and MMP-1 activity.116  
Adenosine has been implicated as a modulator of inflammatory processes central to 
asthma.117 Adenosine is a signalling nucleoside that is generated in hypoxic 
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environments such as that found in the inflamed lung, suggesting that it might serve a 
regulatory role in chronic lung diseases. High expression of this gene is associated 
with persistent lung inflammation and damage. In our findings the gene encoding the 
adenosine deaminase was upregulated in both groups.  
Among the 5 most down regulated genes, adrenomedullin was downregulated in both, 
MCT and MT group. Adrenomedullin is a potent vasodilator peptide that is secreted 
constitutively by vascular endothelial and smooth muscle cells118 and is expressed at 
high levels in the lung.119 The downregulation of adenosine could lead to the restriction 
of vasodilator molecules resulting in an imbalance between vasoconstrictors and 
vasodilators.  
Bone morphogenic proteins (BMPs) play pivotal roles in the regulation of embryonic 
lung development and branching of airways and have recently been considered to 
influence inflammatory processes in adults due to their chemotactic activity on 
fibroblasts, myocytes, and inflammatory cells. BMP-6 or vgr, is a member of the TGF-
beta superfamily appearing to modulate mesenchymal differentiation, including the 
processes of cartilage and bone formation. This factor may be considered as a 
prototype for the largest subgroup of related factors within the TGF-beta superfamily. 
Nothing is yet known about the function of the TGF-beta- related factor vgr, only limited 
studies have been conducted on the most closely related factors BMP-5, osteogenic 
protein-1 (OP-1) or BMP-7, and OP-2. Because vgr-1 mRNA has been localized in 
hypertrophic cartilage, this factor may play a vital role in endochondral bone formation. 
Downregulation of Vgr/BMP-6 suggests that this molecule is involved somewhere in 
TGF-beta signalling pathway to inhibit ongoing BMP signalling and downstream 
intracellular smads process.  
According to our second hypothesis, we did not detect any single gene that was 
attenuated after Tola infusion. Nevertheless, we have detected several genes that are 
regulated in MT and not in MCT (18 genes), and similarly, in MCT and not in MT (67 
genes; see MCT discussion section). Among the 18 genes some gene likes protease 
II, protease inhibitor, stromal cell-derived factor-1 (an angiogenic cytokine), and cell 
division cycle control protein 2 cdc2a may be involved in angiogenesis and vessel 
maintenance. Very interestingly, BMPR2 that was found to be downregulated in the 
MCT group was no longer regulated in the treated group. 
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In the Tola group, we detected (as expected) only a low number of differentially 
regulated genes (19 genes). We further did not detect genes that are involved in MCT 
induced PH, especially no mast cell proteases, tissue inhibitors of metalloproteinases, 
or BMPR-II. Furthermore, we have detected 10 genes that are upregulated in MT in 
similar fashion as well. Such similar behaviour suggests that these genes were 
regulated by Tola influence. Among 10 genes S100A8 and S100A9 were upregulated. 
Recently, pro-inflammatory activities had been described for S100A8 and S100A9, two 
proteins found at inflammatory sites and within the neutrophil cytoplasm. Elevated 
serum levels of S100A8 and S100A9 have been found in patients suffering from a 
number of inflammatory disorders including cystic fibrosis, rheumatoid arthritis and 
chronic bronchitis.120 Upregulation with 3.0-fold of these proteins in MT group suggests 
that S100A8 and S100A9 play a role in the inflammatory response against 
inflammatory agent (MCT) by inducing the release of neutrophils from the bone marrow 
and directing their migration to the inflammatory site. In the Tola group an upregulation 
by a factor of 5.0 suggests that Tola has a very strong influence on recruiting these 
pro-inflammatory proteins while in MT group the increase dropped to the factor of 2.0.  
Another molecule that was regulated in MT and Tola group was Melanocortin 5-
receptor (MC5-R). MC5-R belongs to a family of pro-opiomelanocortin-derived peptides 
that have the melanocyte-stimulating hormone (MSH) core sequence. Melanocortins 
have been described as having a variety of cardiovascular effects.121 Moreover, very 
low expression levels have been detected in brain, while high levels are found in 
adrenals, stomach, lung and spleen.122 This gene was upregulated in MT (Tola) with a 
foldchange of 2.0 (4.0).  
6.3 Pneumolysin-Dependent Gene Expression 
Among different toxins streptococcus pneumoniae is able to synthesize the pore-
forming exotoxin pneumolysin. When investigating the effects of this exotoxin (kindly 
provided by Prof. Dr. T. Chakraborty, Department of Medical Microbiology) we found 
that IT application resulted in severe illness and respiratory distress and lung edma of 
the mice while IV applications of same dosage was tolerated well by the animals 
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(performed by PD Dr. U.A. Maus). Additionally, PLY was applied to the ex-vivo 
ventilated and perfused lung organ model (performed by PD Dr. N. Weissmann). Here, 
IT application showed a remarkable increase in weight by development of an edema 
and significant increase in pulmonary artery pressure (PAP; figure 37 b). Based on 
these observations we investigated the gene expression regulation in the in-vivo and 
ex-vivo model. Only few studies on streptococcus pneumoniae induced transcriptional 
regulation were published. Roger PD et al. differentiated the PLY dependent and PLY 
independent expression changes of streptococcus pneumonaie in mononuclear 
cells.123 
6.3.1 Animal Model (in-vivo) 
Expression profiling was performed on Affymetrix MG U74 Chips. Analyzing the data, 
the hierarchical clustering resulted in a conclusion that there was a high degree of 
similarity between IV group and control group for both the models suggesting that PLY 
application via IV mode does not alter gene expression pattern considerably. The 
reason for this finding might be that PLY in the given dosage is completely bound by 
serum proteins and therefore does not develop effects. Consequently, we put IV and 
control in one group. Afterwards, differential expression of IT group versus control+IV 
group was calculated. As expected, we found several genes that are regulating in PLY 
dependent manner. Lysyl oxidase (LOX), an enzyme secreted by activated vascular 
smooth muscle cells and fibroblasts, was upregulated with a more than a factor of 4.0. 
LOX catalyzes a key step in the cross-linking and stabilization of collagen and elastin in 
the vascular wall and involved in extracellular matrix maturation. Upregulation of LOX 
could be a sign for instability between collagen and elastin in vascular wall and impairs 
the endothelial barrier function and could be involved in homocysteine (HC)-induced 
endothelial dysfunction and leakage.124  
An imbalance between vasoactive and vasocontrictor factors contributes to the 
vascular remodelling and increases pulmonary artery pressure. Among 
vasoconstriction factor, here, angiotensin converting enzyme (ACE) was upregulated. 
ACE is an ectoenzyme that catalyzes the conversion of angiotensin I to the 
vasoconstrictor angiotensin II as well as the degradation of the potent vasodilator 
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bradykinin.125 ACE is thought to play a crucial role in blood pressure regulation and in 
processes involved in vascular remodelling.  
CD53 is also an integral membrane protein. It is expressed on a broad range of 
different hematopoietic cell types, including monocytes and macrophages and is 
involved in association with integrins and protein kinase C to facilitate their interaction 
and thus their engagement in growth regulation of these cells.126-127 Although, its 
biological role remains unknown. Here, the expression of CD53 was upregulated with 
more than a factor of 3.0, suggesting a defence mechanism of lung cells against 
pneumococcus. 
A number of factors involved in cell cycle control were found to be upregulated in a 
PLY-dependent fashion, for example, ubiquitin-conjugating enzyme E2 was 
upregulated. Upregulation of ubiquitin-conjugating enzyme E2 mediating degradation 
of the cyclin-dependent kinase inhibitor p27Kip1 thereby triggering the onset of DNA 
replication and cell cycle progression. Moreover, ubiquitinylation induced proteolysis 
may disrupt cell regulation itself by degradation of regulatory proteins.128  
On the other hand several genes were differentially downregulated in response to PLY. 
Among them, CD84, a newly described cell surface molecule is a member of the CD2 
subset of the immunoglobulin superfamily of cell surface receptors.129 Recently, it had 
been described that CD84 may play a significant role in leukocyte activation.130 Its 
structural similarity with other members of the Ig superfamily as well as the presence of  
four potential SH2 domain binding motifs found in the cytoplasmic domain suggest that 
it may be involved in cellular interactions, activating lymphocytes and natural killer 
cells, and signal transduction.130 Downregulation of CD84 would lead to severe 
curtailment of above processes. 
In conclusion, the found differential expression indicates changes that lead to acute 
disruption of the endothelium barrier and dysregulation of the vascular tone. 
6.3.2 Organ Model (ex-vivo) 
Several genes were regulated after applying PLY via IT mode to the ex-vivo model. 
The first five upregulated genes are troponin T2, myosin heavy chain, cardiac actin, 
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troponin I and myosin light chain. These muscle cell filaments necessary for 
contraction point to an increased pressure that is answered by increased muscle 
filament synthesis. Myosin light chain (MLC) additionally playes a role in maintaining 
endothelium cell (EC) barrier integrity between the vascular spaces and underlying 
tissues. Any compromise of endothelial cell (EC) barrier integrity leads to an increase in 
vascular permeability, a cardinal feature of inflammation resulting in tissue edema and 
hypoxemia. Edemagenic agents such as the serine protease thrombin induce EC 
barrier dysfunction, primarily via actomyosin-driven contraction initiated by myosin light 
chain (MLC) phosphorylation and tightly linked to microfilament reorganization.131   
On the other hand chemokine c-c receptor 1, which may play an important role in lung 
inflammatory cell recruitment because of having a leukocyte chemotactic and activating 
properties, was downregulated in response to PLY via IT. Less is known about the 
relationship of complement activation products to chemokine generation and attendant 
effects on lung injury. Here, downregulation of chemokine c-c gene as well as 
interleukin I receptor suggest an involvement in lung inflammatory cell recruitment 
process and edema induction.132 
In the ex-vivo model and PLY application via IV mode, the toxin via IV mode has 
obviously no strong effects. Few genes were found to be regulated which are 
independent to PLY toxin effect; for example, Bcl-2-associated athanogen was 
upregulated. Bcl-2-associated athanogen consists of a homologous network of genes 
that regulate apoptosis or programmed cell death. Overexpression of Bcl-2 might be 
implicated in genome degradation during apoptosis.  
Next we asked how many genes are regulated commonly in in-vivo and an ex-vivo 
model? Interestingly, no single gene was detected after comparing in-vivo (IT/IV) 
model to an ex-vivo (IV/IVC) group while several genes were detected in in-vivo (IT/IV) 
and an ex-vivo (IT/ITC) group. This suggests that the expression profiling for IT 
application of PLY results in severe changes in-vivo and in an ex-vivo organ model that 
differ remarkably from the IV treatment. PLY toxin via IV mode does not have strong 
influences on these genes.   
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7 Conclusions 
The presented thesis work provides a broad overview of different gene array 
technology platforms. The optimization of glass array technology is shown in a 
stepwise manner. Pitfalls that appeared are shown from the sample preparation of 
different experimenters leading to completely different expression profiles to the cluster 
analysis of affymetrix arrays pointing to a sample mix-up. Moreover, two different RNA 
preamplification techniques were extensively compared due to the generated product 
length, reproducibility, and validity of the correspinding unamplified samples. This 
technical part gives other investigators suggestions how to plan and perform array 
experiments and what details have to be noticed. 
This kind of screening technique was applied to the analysis of two animal models of 
pulmonary hypertension. At first sight, we could not detect new key player genes that 
have not been described yet in the setting of vascular remodelling. On closer 
inspection, a set of genes was found that confirm published knowledge of signalling 
mechanisms during the remodeling process indicating reliable performance of the 
experiments. Furthermore, some genes were found that fit well into the expectations of 
signalling. Especially the downregulation of BMPR2 in the monocrotaline model is an 
interesting finding showing for the first time disease involvement of this receptor in an 
animal model. Nevertheless, an independent confirmation of the RNA regulation should 
be performed before further investigations on protein level (western blot, 
immunohistochemistry) and functional experiments follow. 
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8 Summary 
Differential gene expression can be investigated effectively by microarrays. Therefore, 
the respective technical steps and parameters, in particular RNA extraction, cDNA 
labelling, hybridization and washing for low-fluorescence background on slides have to 
be optimized. Comparing different RNA extraction techniques, we found that Trifast™ 
method followed by column purification combined with DNase digestion resulted in 
highest RNA quality of the samples. Ten to 20 µg RNA, direct labelling of the RNA with 
Cy-dNTPs and SuperScript II reverse transcriptase generated an efficient incorporation 
rate and sufficient amounts of labelled samples for microarray analysis. Furthermore, 
technical parameters of the hybridization process were adapted to optimize the signal 
to noise ratio. Particular importance was addressed to the comparison of RNA 
preamplification methods that allow the use of trace amounts of sample material for 
array analyses. Starting from as few as 50 ng initial total RNA, the performance of two 
preamplification techniques, two rounds of T7 based In-vitro transcription and PCR 
based SMART™ amplification were compared due to 1) the length of the generated 
products, 2) the inter-assay reproducibility using two independently performed 
repetition of the hybridization experiments, and 3) the validity of the expression profile 
when compared to the identical unamplified samples. We could show that the 
sequences close to the polyA-tail (<1kb distance) were amplified in two rounds IVT by 
a factor of 300-1000, comparable to the factor obtained by 12 cycles SMART™. In 
contrast, sequences with a distance of >1kb from the polyA-tail were only <100-fold 
amplified by IVT but again about 1000-fold with 12 cycles SMART™. The 
reproducibility of SMART™ was higher (R²=0.91) than of IVT (R²=0.68). Finally, higher 
correlation was seen for the comparison of SMART™ amplified samples to unamplified 
material versus IVT samples. Thus, SMART™ turned out to be superiour for minute 
amounts of total RNA (~ 50 ng) when introducing to microarray experiments. 
Applying our established cDNA-macroarrays and oligonucleotide-microarrays to 
investigate pulmonary hypertension we expected to expand our knowledge about the 
disease signalling pathways. Differential gene expression was studied using a rat 
model of monocrotaline-induced pulmonary hypertension and attenuation of the 
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disease by application of the phosphodiesterase inhibitor tolafentrine. In cDNA 
macroarrays with 1,176 genes, we detected 11 regulated genes after monocrotaline 
treatment and 3 after treatment with monocrotaline together with tolafentrine. Using 
microarrays with 10,000 spotted sequences, we detected 103 and 54 regulated genes, 
respectively. Interestingly, tolafentrine given alone had only little influence on the 
expression profile.  
In the second model of pulmonary hypertension pneumolysin, a pore-forming exotoxin 
of Streptococcus pneumoniae was instillated intratreacheally (IT) or intravenously (IV) 
to mice. While IT application resulted in severe illness and respiratory distress, IV 
application was tolerated well. Differential gene expression of lung homogenates was 
analysed by Affymetrix GeneChips™. Afterwards, IT and IV instillation was applied to 
an ex-vivo ventilated and perfused lung organ model. Here, IT application resulted in 
significant increase of pulmonary artery pressure and lung oedema. Comparing 
expression profiles after in-vivo application to that of the ex-vivo treated lungs showed 
more than 100 genes regulated in the IT groups of both models. In contrast, the 
profiles differed remarkably to those of IV treatment, where only minor changes in the 
expression profiles were observed in comparison to the controls. 
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9 Zusammenfassung 
Mikroarrays erlauben eine effektive Untersuchung differenzieller Genexpression. 
Zunächst müssen hierzu jedoch die entsprechenden technischen Schritte und Para-
meter, insbesondere die RNA Extraktion, die Markierung der cDNA, die Hybridisierung 
sowie Waschschritte zur Minimierung des Hintergrunds auf den Objektträgern optimiert 
werden. Beim Vergleich verschiedener RNA Extraktionsprotokolle fanden wir, dass die 
Trifast™ Methode mit anschließender Silicasäulenaufreinigung und kombiniertem 
DNase Verdau die höchste RNA Qualität ergab. Einsatz von 10 bis 20 µg RNA, die 
Verwendung Cy-gekoppelter dNTPs sowie die SuperScript II reverse Transkriptase 
resultierten in einer effizienten Einbaurate und ausreichenden Mengen an markierter 
cDNA für die anschließende  Mikroarray Hybridisierung. Zudem mussten aber auch die 
technischen Parameter dieses Hybridisierungsprozesses ausgetestet werden, um den 
Quotienten von Signal/Hintergrund zu optimieren. 
Ein besonderes Augenmerk wurde auf den Vergleich von RNA Präamplifikations-
techniken  gelegt, die das Einsetzen auch geringer RNA Mengen in Array Experimente 
erlauben. Ausgehend von nur 50 ng Gesamt-RNA wurden als Präamplifikations-
techniken zwei Runden der T7 basierten In-vitro Transkription (IVT)  mit der PCR 
basierten SMART™ PCR verglichen bezüglich 1) der Länge der generierten Produkte, 
2) ihrer (inter-assay) Reproduzierbarkeit bei jeweils zwei unabhängig voneinander 
durchgeführten Hybridisierungsexperimenten sowie 3) der Validität der 
Expressionprofile im Vergleich zu Profilen von identischen unamplifizierten Proben. Wir 
konnten dabei zeigen, dass Sequenzen nahe des poly-A-Schwanzes (<1kb Abstand) 
mit zwei Runden IVT um einen Faktor von 300-1000 amplifiziert wurden, vergleichbar 
zu dem mit 12 Zyklen SMART™ erzielten Ergebnis. Dagegen wurden Sequenzen mit 
einem Abstand von >1kb vom poly-A-Schwanz durch die IVT weniger als 100-fach 
amplifiziert, während 12 Zyklen SMART™ wiederum eine Vervielfältigung um Faktor 
1000 zeigten. Zudem erwies sich die Reproduzierbarkeit von SMART™ (R²=0.91) 
höher als die der IVT (R²=0.68). Schließlich erwies sich auch die Korrelation beim 
Vergleich von SMART™ amplifizierten Proben zu ihren unamplifizierten Pendants als 
höher als der entsprechende Ansatz mit IVT Proben. Insofern bleibt festzuhalten, dass 
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die SMART™ Amplifikation bei sehr geringen initialen RNA Mengen (~ 50 ng) der IVT 
über zwei Runden für Hybridisierungsexperimente deutlich überlegen ist. 
Anschließend wurden die in der Arbeitsgruppe bereits etablierten Nylon-Membran 
basierten Makroarrays sowie die neu optimierten Oligonukleotid-Mikroarrays einge-
setzt, um pulmonalarterielle Hypertonie in zwei Tiermodellen zu untersuchen und 
mögliche Signalkaskaden aufzufinden. Zum einen kam das Rattenmodell der Mono-
krotalin-induzierten pulmonalen Hypertonie zur Verwendung sowie deren Abschwäch-
ung durch Gabe des Phosphodiesterase Inhibitors Tolafentrine. Mittels cDNA Makro-
arrays mit 1,176 gespotteten Genen detektierten wir 11 regulierte Gene in Lungen von 
Monokrotalin-behandelten Ratten sowie 3 Gene in Lungen von Ratten, denen Mono-
krotalin und Tolafentrine appliziert wurde. Bei Einsatz der Mikroarrays mit 10,000 
gespotteten Sequenzen fanden wir 103 regulierte Gene in erstbeschriebener und 54 in 
zweitbeschriebener Gruppe. Interessanterweise hatte die alleinige Gabe von 
Tolafentrine nur einen geringen Effekt auf die Expressionsprofile.  
Im zweiten Modell der pulmonalarteriellen Hypertonie wurde Pneumolysin, ein poren-
bildendes Exotoxin von Streptococcus pneumoniae, Mäusen entweder intratracheal 
(IT) oder intravenös (IV) instilliert.  Während die IT Gabe zu schwerer Erkrankung und 
Luftnot führte, verhielten sich die Tiere nach IV Gabe unauffällig. Die differenzielle 
Genexpression der Lungenhomogenate wurde mittels Affymetrix GeneChips™ unter-
sucht. Zudem erfolgte auch die IT und IV Instillation am Organmodell der ex-vivo 
ventilierten und perfundierten Lunge. Dabei resultiere die IT Applikation in einem 
signifikanten Anstieg des pulmonalarteriellen Druckes und Ausbildung eines Lungen-
ödems. Der Vergleich der Expressionsprofile nach in-vivo Applikation zu denen von ex-
vivo behandelten Lungen zeigte mehr als 100 Gene reguliert in den IT Gruppen beider 
Modelle. Im Gegensatz hierzu unterschieden sich die Profile beträchtlich zu denen 
nach IV Behandlung, wobei insgesamt nur geringe Veränderungen letztgenannter 
Expression gegenüber den Kontrollen zu beobachten waren. 
  104
10 References 
1. Schena, M., Shalon, D., Davis, R.W., Brown, P.O. Quantitative monitoring of 
gene expression patterns with a complementary DNA microarray. Science 
1995, 270:467-470 
2. Shioda, T. Application of DNA microarray to toxicological research. J Environ 
Pathol Toxicol Oncol 2004, 23:13-31 
3. Carella, M., Volinia, S., Gasparini, P. Nanotechnologies and microchips in 
genetic diseases. J Nephrol 2003, 16:597-602 
4. Chin, KV., Kong, AN. Application of DNA microarrays in pharmaco genomics 
and toxicogenomics. Pharm Res 2002, 19:1773-1778 
5. Butte, A. The use and analysis of microarray data. Nat Rev Drug Discov 2002 
1:951-960 
6. Pollock, JD. Gene expression profiling: methodological challenges, results, and 
prospects for addiction research. Chem Phys Lipids  2002, 121:241-256 
7. Jenkins, ES., Broadhead, C., Combes, RD. The implications of microarray 
technology for animal use in scientific research. Altern Lab Anim 2002, 30:459-
465 
8. Xiang, Z., Yang Y., Ma, X., Ding, W. Microarray expression profiling: Analysis 
and applications. Curr Opin Drug Discov Devel  2003, 6:384-395 
9. http://www.ncbi.nlm.nih.gov/entrez/  
10. Southern, EM. Detection of Specific Sequences among DNA Fragments 
Separated by Gel Electrophoresis. Journal of Molecular Biology 1975, 98:503-
517 
11. Dubitsky, A., Defiglia, J. Stripping of Digoxigenin-Labelled Probes from Nylon 
Membranes. BioTechniques 1995, 19:210-212 
12. Noppinger, K., Duncan, G., Ferraro, D. Evaluation of DNA Probe Removal from 
Nylon Membrane. BioTechniques 1992, 13:572-575 
13. Fodor, S., Read, JL., Pirrung, MC., Stryer, L.., Tsai, Lu A., Solas, D. Light-
directed, spatially addressable parallel chemical synthesis. Science 1991, 251: 
767-773 
14. Pease, AC., Solas, D., Sullivan, EJ., Cronin, MT., Holmes, CP., Fodor, SPA. 
Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc 
Natl Acad Sci USA 1994, 91:5022-5026 
15. Barone, AD. Photolithographic synthesis of high-density oligonucleotide probe 
arrays. Nucleosides Nucleotides Nucleic Acids 2001, 20:525-531 
16. Wong, KK., Tsang, YT., Shen, J., Cheng, RS., Chang, YM., Man, TK., Lau CC. 
Allelic imbalance analysis by high-density single-nucleotide polymorphic allele 
  105
(SNP) array with whole genome amplified DNA. Nucleic Acids Res 2004, 
32:e69 
17. Rubin, L. ACCP consensus statement; primary pulmonary hypertension. Chest 
1987, 104:236-250 
18. Edwards, WD., Edwards, JE. Clinical primary pulmonary hypertension: three 
pathologic types. Circulation 1977, 56:884-888 
19. Romberg, E. Ueber sklerose der lungen arterie. Dtsch Archiv Klin Med 1891, 
48:197-206 
20. Dresdale, DT., Schultz, M., Michtom, RJ. Primary pulmonary hypertension: 
Clinical and haemodynamic study. Am J Med 1951, 11:686-705 
21. Dresdale, DT., Michtom, RJ., Schultz, M. Recent studies In PPH, including 
pharmacodynamics observations on pulmonary vascular resistance. Bull NY 
Acad Med 1954, 30:195-207 
22. Rich, S., Dantzker, D., Aryers, SM. Primary Pulmonary Hypertension: a national 
prospective study. Ann Intern med 1987, 107:216-223 
23. Loyd, JE., Butler, MG., Foroud, TM., Conneally, PM., Phillips, JA., Newman, 
JH. Genetic anticipation and abnormal gender ratio at birth in familial primary 
pulmonary hypertension. Am J Respir Crit Med 1995, 152:93-97 
24. Wood, P. Pulmonary hypertension with special reference to the vasoconstrictive 
factor. Br Heart J 1958, 2:557-570 
25. Rubin, LJ. Diagnosis and Management of Pulmonary Arterial hypertension: 
ACCP Evidence-Based Practical Guidelines. Chest 2004, 126:7S-10S 
26. Romberg, E. Ueber slerose der lungenarterien. Dtsch Arch Klin Med 1891, 
48:197-199 
27. Chazova, I., Loyd, JE., Zhdanov, VS., Newman, JH., Belenkov, Y., Meyrick, B. 
Pulmonary artery adventitial changes and venous involvement in PPH. Am J 
Pathol 1995, 146:389–397 
28. Cool, CD., Stewart, JC., Werahera, P., Miller, GJ., Williams, RL., Voelkel NF., 
Tuder, RM. Three-dimensional reconstruction of pulmonary arteries in plexiform 
pulmonary hypertension using cell-specific markers. Am J Pathol 1999, 
155:411-419 
29. Voelkel, NF., Cool, C., Lee, SD., Wright, L., Geraci, MW., Tuder, RM. Primary 
pulmonary hypertension between inflammation and cancer. Chest 1998, 
114:225S-230S 
30. Deng, Z., Morse, JH., Slager, SL., Cuervo, N., Moore, KJ., Venetos, G., 
Kalachikov, S., Cayanis, E., Fischer, SG., Barst, RJ., Hodge, SE., Knowles, JA. 
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations 
in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 
67:737-744 
  106
31. Strange, JW., Wharton, J., Philips, PG., Wilkins, MR. Recent insights into the 
pathogenesis and therapeutics of pulmonary hypertension. Clinical Science 
2002, 102:253-268   
32. Will, DH., Alexander, AF., Reeves, JT., Grover, RF. High altitude-induced 
pulmonary hypertension in normal cattle. Circ. Res 1962, 10:172-177 
33. Huxtable, RJ. Activation and pulmonary toxicity of pyrrolizidine alkaloids. 
Pharmacol Ther 1990, 47:371-389 
34. Roth, RA., Reindel, JF. Lung vascular injury from monocrotaline pyrrole, a 
putative hepatic metabolite. Adv Exp Med Biol 1991, 283:477-487 
35. Schermuly, RT., Kreisselmeier, KP., Ghofrani, HA., Yilmaz, H., Butrous, G., 
Ermert, L., Ermert, M., Weissmann, N., Rose, F., Guenther, A., Walmrath, D., 
Seeger, W., Grimminger, F. Chronic sildenafil treatment inhibits MCT-induced 
pulmonary hypertension in rats. Am J Respir Crit Care Med 2004, 169:39-45 
36. Wilson, DW., Segah, HJ., Pan, LCW. Progressive inflammatory and skeletal 
changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc 
Res 1989, 80:1207-1221 
37. Romberg, E. Ueber slerose der lungenarterien. Dtsch Arch Klin Med 1891, 
48:197-199  
38. Chazova, I., Loyd, JE., Zhdanov, VS., Newman, JH., Belenkov, Y., Meyrick, B. 
Pulmonary artery adventitial changes and venous involvement in PPH. Am J 
Pathol 1995, 146:389-397 
39. Rosenberg, HC., Rabinovitch, M. Endothelial injury and vascular reactivity in 
monocrotaline pulmonary hypertension. Am J Physiol 1988, 255:1484-1491 
40. Reindel, JF., Ganey, PE., Wagner, JG., Slocombe, RF., Roth, RA. 
Development of morphologic, hemodynamic, and biochemical changes in lungs 
of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol 1990, 106:179-200  
41. Dorfmüller, P., Perros, F., Balabanian, K., and Humbert, M. Inflammation in 
pulmonary arterial hypertension. Eur Respir J 2003, 22:358-363   
42. Christman, BW., McPherson, CD., Newman, JH., King, GA., Bernard, GR., 
Groves, BM., Loyd, JE. An imbalance between the excretion of thromboxane 
and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 
327:70-75 
43. Wagner, RS., Smith, CJ., Taylor, AM., Rhoades, RA. Phosphodiesterase 
inhibition improves agonist-induced relaxation of hypertensive pulmonary 
arteries. J Pharmacol Exp Ther 1997, 282:1650-1657 
44. Uder, M., Heinrich, M., Jansen, A., Humke, U., Utz, J., Trautwein, W., Kramann, 
B. cAMP and cGMP do not mediate the vasorelaxation induced by iodinated 
radiographic contrast media in isolated swine renal arteries. Acta Radiol 2002, 
43:104-110 
45. De Boer, J., Philpott, KJ, Van Amsterdam, RGM., Shahid, M., Zaagsma, J.,  
Nicholson, CD. Human bronchial cyclic nucleotide phosphodiesterase 
  107
isoenzymes: Biochemical and pharmacological analysis using selective 
inhibitors. Br J Pharmacol 1992, 106:1028-1034 
46. Torphy, TJ. Phosphodiesterase isoenzymes. Am J Respir Crit Care Med 1998, 
157:351-370 
47. Schermuly, RT., Roehl, A., Weissmann, N., Ghofrani, HA., Schudt, C., Tenor. 
H., Grimminger, F., Seeger, W., Walmrath, D. Subthreshold doses of specific 
phosphodiesterase type 3 and 4 inhibitor enhance the pulmonary vasodilatory 
response to nebulized prostacyclin with improvement in gas exchange. JPET 
2000, 292:512-520 
48. Hoeper, MM., Galie, N., Simonneau, G., Rubin, LJ. New treatment for 
pulmonary arterial hypertension. Am J Respir Crit Care Med 2002, 165:1209-
1216 
49. Johnston, RB. Pathogenesis of pneumococcal pneumonia. Jr Rev Infect Dis 
1991, 13:S509-S517 
50. Qadri, SM., Berotte, JM., Wende, RD. Incidence and etiology of septic 
meningitis in a metropolitan county hospital. Am J Clin Pathol 1976, 65:550-556 
51. Klein, JO. The epidemiology of pneumococcal disease in infants and children. 
Rev Infect Dis 1981, 3:246-253 
52. Yangco, BG., Deresinski, SC. Necrotizing or cavitating pneumonia due to 
Streptococcus Pneumoniae: report of four cases and review of the literature. 
Medicine (Baltimore) 1980, 59:449-457 
53. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., Kirschning, CJ. 
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-
like receptor 2. J Biol Chem 1999, 274:17406-17409 
54. Jedrezejas, MJ. Pneumococcal virulence factors: structure and function. 
Microbiol Mol Biol Rev 2001, 65:187-207 
55. McDaniel, LS., Thornton, JA., McDaniel, DO. Use of cDNA microarrays to 
analyze responses to pneumococcal virulence factors. Indian J Med Res 2004, 
119:99-103 
56. Paton, JC. The contribution of pneumolysin to the pathogenicity of 
Streptococcus pneumoniae. Trends Microbiol 1996, 4:103-106 
57. Rossjohn, J., Feil, SC., McKinstry, WJ., Tweten, RK., Parker, MW. Structure of 
a cholesterol-binding, thiol-activated cytolysin and a model of its membrane 
form. Cell 1997, 89:685-692 
58. Bhakdi, S., Tranum-Jensen, J. Alpha-toxin of Staphylococcus aureus. 
Microbiological Reviews 1991, 55:733-751 
59. Chomczynski, P., Sacchi, N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem 1987, 
162:156-159 
  108
60. Van Gelder, RN., Von Zastrow, ME., Yool, A., Dement, WC., Barchas, JD., 
Eberwine, JH. Amplified RNA synthesized from limited quantities of 
heterogeneous cDNA. Proc Natl Acad Sci USA 1990, 87:1663-1667 
61. Eberwine, J. Amplification of mRNA populations using aRNA generated from 
immobilized oligo-dT-T7 primed cDNA. BioTechniques 1996, 20:584-591 
62. Zhumabayeva, B., Chenchik, A., Siebert, PD., Herrler, M. Disease profiling 
arrays: reverse format cDNA arrays complimentary to microarrays. Adv 
Biochem Eng BioTechnol 2004, 86:191-213 
63. Seth, D., Gorrell, MD., McGuinness, PH., Leo, MA., Lieber, CS., McCaughan, 
GW., Haber, PS. SMART amplification maintains representationof relative gene 
expression: quantitative validation by real time PCR and application to studies 
of alcoholic liver disease in primates. Biochem Biophys Methods 2003, 55:53-
66  
64. Eberwine, J., Yeh, H., Miyashiro, K., Cao, Y., Nair, S., Finnell, R., Zettel, M., 
Coleman, P. Analysis of gene expression in single live neurons. Proc Natl Acad 
Sci USA 1992, 89:3010–3014.  
65. Chenchik, A. Clontechniques IX (1) 1998, 9–12  
66. Freeman, WM., Walker, SJ., Vrana Freeman, KE. Quantitative RT-PCR: pitfalls 
and potential. BioTechnique 1999, 26:112-122 
67. http://www.r-project.org/ and http://www.bioconductor.org/ 
68. Smyth, GK., Michaud, J., Scott, H. The use of within-array replicate spots for 
assessing differential expression in microarray experiments. Bioinformatics 
2005, 21:2067-2075 
69. Smyth, GK., Speed, TP. Normalization of cDNA microarray data. Methods 
2003, 31:265-273 
70. Smyth, GK. Limma: linear models for microarray data. In: Bioinformatics and 
Computational Biology Solutions using R and Bioconductor, R. Gentleman, V. 
Carey, S. Dudoit, R. Irizarry, W. Huber (eds.), Springer, New York, Chapter 23. 
(To be published in 2005) 
71. Yang, YH., Dudoit, S., Luu, P., Lin, DM., Peng, V., Ngai, J., Speed, TP.  
Normalization for cDNA microarray data: a robust composite method 
addressing single and multiple slide systematic variation. Nucleic Acids 
Research 2002, 30:e15 
72. Cleveland, WS. Robust locally weighted regression and smoothing scatterplots. 
Jour Amer Stat Assoc 1979, 74:829-836 
73. Smyth, GK. Linear Models and Empirical Bayes Methods for Assessing 
Differential Expression in Microarray Experiments. Statistical Applications in 
Genetics and Molecular Biology 2004, 3: Issue 1 
74. http://www.dchip.org/ 
75. Bustin, SA. Absolute quantification of mRNA using reverse transcription 
polymerase chain reaction assays. Jour Mol Endocrinol 2000, 25:169-193 
  109
76. Tavangar, K., Hoffman, AR., Kraemer, FB. A micromethod for the isolation of 
total RNA from adipose tissue. Anal Biochem 1990, 186:60-63 
77. Smale, G., Sasse, J. RNA isolation from cartilage using density gradient 
centrifugation in cesium trifluoroacetate: an RNA preparation technique 
effective in the presence of high proteoglycan content. Anal Biochem 1992, 
203:352-56 
78. Briscoe, PR., Jorgensen, TJ. Improved RNA isolation from cells in tissue culture 
using a commercial nucleic acid extractor. BioTechniques 1991, 10:594-96 
79. http://homer.hsr.ornl.gov/CBPS/Arraytechnology/Hyb.html 
80. http://www.bri.nrc.gc.ca/pdf/microarray_Direct_Incorporation_Labeling%20_Pro
tocol_e.doc 
81. Mateos, A. Effect of ethanol consumption on adult rat liver mitochondrial 
population analyzed by flow cytometry. Alcohol Clin Exp Res 1995, 19:1327-
1330 
82. Velculescu, VE., Zhang, L., Vogelstein, B., Kinzler, KW. Serial analysis of gene 
expression. Science 1995, 270:484-487 
83. Watson, A., Mazumder, A., Stewart, M., Balasubramanian, S. Technology for 
microarray analysis of gene expression. Curr Opin Biotechnol 1998, 9:609-614 
84. Luo, L., Salunga, RC., Guo, H., Bittner, A., Joy, KC., Galindo, JE., Xiao, H., 
Rogers, KE., Wan, JS., Jackson, MR.,Erlander, MG. Gene expression profiles 
of laser-captured adjacent neuronal subtypes. Nat Med 1999, 5:117-122 
85. http://www.ncbi. nlm. nih.gov /Uni Gene /ddd.cgi AND http://genecards.weiz 
mann. ac.il/cgi-bin/ genenote 
86. Morrison, DA., Ellis, JT. The Design and Analysis of Microarray Experiments: 
Applications in Parasitology. DNA and Cell Biology, 2003, 226:357-394 
87. Saghizadeh, M., Brown, DJ., Tajbakhsh, J., Chen, Z., Kenney, MC., Farber, 
DB., Nelson, SF. Evaluation of techniques using amplified nucleic acid probes 
for gene expression profiling. Biomolecular Engineering 2003, 20:97-106 
88. www.arctur.com 
89. Wang E., Miller, LD., Ohnmacht, G.A., Liu, E.T., Arincola, FM. High-fidelity 
mRNA amplification for gene profiling. Nat Biotechnol 2000, 18:457-459 
90. Wilson, CL., Pepper, SD., Hey, Y., Miller, CJ. Amplification protocols introduce 
systematic but reproducible errors into gene expression studies. BioTechniques 
2004, 36:498-506 
91. Schneider, J., Buness, A., Huber, W., Volz, J., Kioschis, P., Hafner, M., 
Poustka, A., Sultmann, H. Systematic analysis of T7 RNA polymerase based in-
vitro linear RNA amplification for use in microarray experiments. BMC 
Genomics 2004, 5:29-38 
92. Stenmark, KR., Durmowicz, AG., Dempsey, EC. Modulation of vascular wall cell 
phenotype in pulmonary hypertension. Portland Press Ltd, London 1995, 171-
212 
  110
93. Huxtable, RJ. Activation and pulmonary toxicity of pyrrolizidine alkaloids. 
Pharmacol Ther 1990, 47:371–389 
94. Tohda, Y. Role of GABA receptors in the bronchial response: studies in 
sensitized guinea-pigs. Clin Exp Allergy 1998, 28:772-77 
95. Capelli, A., Lusuardi, M., Cerutti, CG., and Donner, CF. Lung alkaline 
phosphatase as a marker of fibrosis in chronic interstitial disorders. Am J Respir 
Crit Care Med 1997, 155:249-253 
96. Arcot, SS. Alterations of growth factor transcripts in rat lungs during 
development of monocrotaline-induced pulmonary hypertension. Biochem 
Pharmacol 1993, 46:1086-91 
97. Geraci, MW., Moore, M., Gesell, T., Yeager, ME., Alger, L., Golpon, H., Gao, 
B., Loyd, JE., Tuder, RM., Voelkel, NF. Gene Expression Patterns in the Lungs 
of Patients with Primary Pulmonary Hypertension. Circ Res 2001, 88:555-562 
98. Meyrick, B., Reid, L. The effect of continued hypoxia on rat pulmonary arterial 
circulation: An ultrastructural study. Lab Invest 1978, 38:188-199 
99. Voelkel, NF., Tuder, RM., Bridges, J., Arend, WP. Interleukin-1 receptor 
antagonist treatment reduces pulmonary hypertension generated in rats by 
monocrotaline. Am J Respir Cell Mol Biol 1994, 11:664-675 
100. Wright, L., Tuder, RM., Wang, J., Cool, CD., Lepley, RA., Voelkel, NF. 5-
Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in 
lungs from patients with primary pulmonary hypertension. Am J Respir Crit 
Care Med 1998, 157:219-229  
101. Vaszar, LT., Nishimura, T., Storey, JD., Zhao, G., Qiu, D., Faul, JL., Pearl, RG., 
Kao, PN. Longitudinal transcriptional analysis of developing neointimal vascular 
occlusion and pulmonary hypertension in rats. Physiol Genomics 2004, 17:150-
156  
102. Ye,C., Rabinovitch, M. Inhibition of elastolysis by SC-37698 reduces 
development and progression of monocrotaline pulmonary hypertension. Am J 
Physiol 1991, 261:12551267 
103. Cowan, KN., Heilbut, A., Humpl, T., Lam, C., Ito, S., Rabinovitch, M. Complete 
reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. 
Nat Med 2000, 6:698-702 
104. Kleiner, DE., Stetler-Stevenson, WG. Structural biochemistry and activation of 
matrix metalloproteases. Curr Opin Cell Biol 1993, 5:891-897 
105. Docherty, AJP., Lyons, A., Smith, BJ., Wright, EM., Stephens, PE., Harris, TJR. 
Sequence of human tissue inhibitor of metalloproteinases and its identity to 
erythroid-potentiating activity. Nature 1985, 318:66-69 
106. Dempsey, EC., Stenmark, KR., McMurtry, IF., O’Brien, RF., Voelkel, NF., 
Badesch, DB. Insulin-like growth factor-I and protein kinase C activation 
stimulate pulmonary artery smooth muscle cell proliferation through separate 
but synergistic pathways. J Cell Physiol 1990, 144:159-165 
  111
107. Olbruck, H., Seemayer, NH., Voss, B., Wilhelm, M. Supernatants from quartz 
dust treated human macrophages stimulate cell proliferation of different human 
lung cells as well as collagen-synthesis of human diploid lung fibroblasts in-
vitro. Toxicol Lett 1998, 96-97:85-95 
108. Kagi, JHR. Evolution, structure and chemical activity of class I metallothioneins: 
an Overview, In: Metallothionein, vol. III (K.T Suzuki, N. Imura and M. Kimura, 
eds.). Berlin: Birkhausen Verlag 1993, pp29-56  
109. Ebadi, M., Iversen, PL., Hao, R., Cerutis, DR., Rojas, P., Happe, HK., Murrin, 
LC., Pfeiffer, RF. Expression and regulation of brain metallothionein. 
Neurochem Int 1995, 27:1-22  
110. Bacqueville, D., Casagrande, F., Perret, B., Chap, H., Darbon, JM., Breton-
Douillon, M. Phosphatidylinositol 3-kinase inhibitors block aortic smooth muscle 
cell proliferation in mid-late G1 phase: effect on cyclin-dependent kinase 2 and 
the inhibitory protein p27KIP1. Biochem Biophys Res Commun 1998, 244:630-
636 
111. Blackshaw, S., Sawa, A., Sharp, AH., Ross, CA., Snyder, SH., Khan, AA. Type 
3 inositol 1,4,5-trisphosphate receptor modulates cell death. FASEB J 2000, 
14:1375-1379  
112. Yamamoto-Hino, M., Sugiyama, T., Hikichi, K., Mattei, MG., Hasegawa, K., 
Sekine, S., Sakurada, K., Miyawaki, A., Furuichi, T., Hasegawa, M. Cloning and 
characterization of human type 2 and type 3 inositol 1,4,5-trisphosphate 
receptors. Receptors Channels 1994, 2:9-22  
113. Oike, Y., Ito, Y., Hamada, K., Zhang, XQ., Miyata, K., Arai, F., Inada, T., Araki, 
K., Nakagata, N., Takeya, M., Kisanuki, YY., Yanagisawa, M., Gale, NW.,  
Suda, T. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 
signalling between endothelial cells and surrounding mesenchymal cells. Blood 
2002, 100:1326-1333 
114. Thomson, JR., Machado, RD., Pauciulo, MW., Morgan, NV., Humbert, M., 
Elliot, GC., Ward, K., Yacoub, M., Mikhail, G., Rogers, P., Newman, J., 
Wheeler, L., Higenbottam, T., Gibbs, JS., Egan, J., Crozier, A., Peacock, A., 
Allcock, R., Corris, P., Loyd, JE., Trembath, RC., Nichols, WC. Sporadic 
primary pulmonary hypertension is associated with germline mutations of the 
gene encoding BMPR-II, a receptor member of the TGF-beta family. Jour Med 
Genet 2000, 37:741-745  
115. Massague, J., Blain, SW., Lo, RS. TGF-beta signalling in growth control, 
cancer, and heritable disorders. Cell 2000, 103:295-309 
116. Kohyama, T., Liu, X., Zhu, YK., Wen, FQ., Wang, HJ., Fang, Q., Kobayashi, T., 
Rennard, SI. Phosphodiesterase 4 Inhibitor Cilomilast Inhibits Fibroblast-
Mediated Collagen Gel Degradation Induced by Tumor Necrosis Factor-and 
Neutrophil Elastase. Am J Respir Cell Mol Biol 2002, 27:487-494  
117. Cushley, MJ., Tattersfield, AE., Holgate, ST. Inhaled adenosine and guanosine 
on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 
1983, 15:161-165  
  112
118. Sugo, S., Minamino, N., Shoji, H., Kangawa, K., Kitamura, K., Eto, T., Matsuo, 
H. Production and secretion of adrenomedullin from vascular smooth muscle 
cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys 
Res Commun 1994, 203:719-726 
119. Kitamura, K., Sakata, J., Kangawa, K., Kojima, M., Matsuo, H., Eto, T. Cloning 
and characterization of cDNA encoding a precursor for human adrenomedullin. 
Biochem Biophys Res 1993, 194:720-725  
120. Sorg, C. The calcium binding proteins S100A8 and S100A9 in acute and 
chronic inflammation. Behring Inst Mitt 1992, 91:126-137  
121. Versteeg, DH., Van Bergen, P., Adan, RA., De Wildt, DJ. Melanocortins and 
cardiovascular regulation: The MC5-R mediates increase in cAMP 
accumulation with a characteristic pharmacology. Eur J Pharmacol 1998, 
360:1-14  
122. Griffon, N., Mignon, V., Facchinetti, P., Diaz, J., Schwartz, JC., Sokoloff, P. 
Molecular cloning and characterization of the rat fifth melanocortin receptor. 
Biochem Biophys Res Commun 1994, 200:1007-1014   
123. Rogers, PD., Thornton, J., Barker, KS., McDaniel, DO., Sacks, GS., Swiatlo, E., 
McDaniel, LS. Pneumolysin-Dependent and -Independent Gene Expression 
Identified by cDNA Microarray Analysis of THP-1 Human Mononuclear Cells 
Stimulated by Streptococcus pneumoniae. Infection and Immunity 2003, 
71:2087-2094  
124. Raposo, B., Rodriguez, C., Martinez-Gonzalez, J., Badimon, L. High levels of 
homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in 
vascular endothelial cells. Atherosclerosis 2004, 177:1-8  
125. Jaspard, E., Costerousse, O., Wei, L., Corvol, P., Alhenc-Gelas, F. The 
angiotensin I-converting enzyme (kininase II): molecular and regulatoryaspects. 
Agents Actions Suppl 1992, 38:349-358  
126. Olweus, J., Lund-Johansen, F., Horejs, V. CD53, a protein with four membrane-
spanning domains, mediates signal transduction in human monocytes and B 
cells. J Immunol 1993, 151:707-716  
127. Zhang, XA., Bontrager, AL., Hemler, ME. Transmembrane-4 superfamily 
proteins associate with activated protein kinase C (PKC) and link PKC to 
specific beta (1) integrins. J Biol Chem 2001, 276:25005-25013 
128. Butz, N., Ruetz, S., Natt, F., Hall, J., Weiler, J., Mestan, J., Ducarre, M., 
Grossenbacher, R., Hauser, P., Kempf, D., Hofmann, F. The human ubiquitin-
conjugating enzyme Cdc34 controls cellular proliferation through regulation of 
p27Kip1 protein levels. Exp Cell Res 2005, 303:482-493 
129. Davis, SJ., Vander Merwe, PA. The structure and ligand interactions of CD2: 
implications for T-cell function. Immunol Today 1996, 617:177-187 
130. de la Fuente, MA., Pizcueta, P., Nadal, M., Bosch, J., Engel, P. CD84 
Leukocyte Antigen Is a New Member of the Ig Superfamily. Blood 1997, 
90:2398-2405   
  113
131. Verin, AD., Birukova, A., Wang, P., Liu, F., Becker, P., Birukov, K., Garcia, Joe 
G. N. Microtubule disassembly increases endothelial cell barrier dysfunction: 
role of MLC phosphorylation. Am J Physiol Lung Cell Mol Physiol 2001, 
281:565-574 
132. Proost, P., Wuyts, A., Van Damme, J. The role of chemokines in inflammation. 
Int J Clin Lab Res 1996, 26:211-223   
 
  114
Eidesstattliche Erklärung 
Ich erkläre: Ich habe die vorgelegte Dissertation selbständig, ohne unerlaubte fremde 
Hilfe und nur mit den Hilfen angefertigt, die ich in der Dissertation angegeben habe. 
Alle Textstellen, die wörtlich oder sinngemäß aus veröffentlichten oder nicht 
veröffentlichten Schriften entnommen sind, und alle Angaben, die auf mündlichen 
Auskünften beruhen, sind als solche kenntlich gemacht. Bei den von mir 
durchgeführten und in der Dissertation erwähnten Untersuchungen habe ich die 
Grundsätze guter wissenschaftlicher Praxis, wie sie in der „Satzung der Justus-Liebig-
Universität Gießen zur Sicherung guter wissenschaftlicher Praxis“ niedergelegt sind, 
eingehalten. 
 
 
 
 
 
Place: Giessen, 2005 
         Signature 
 
 
  115
Curriculum Vitae 
Name: Jai Prakash  
Date of Birth: 04-09-1974 
Address: 34/4, Block No.4, Teg Bahadur Road, Dalanwala, 
Dehradun, Uttaranchal, India 
E-mail: jai_muyal@yahoo.com 
Telephone No:    +91-135 –2676904 (Home) 
                                                  
SCHOOL EDUCATION: 
1981-90 From 1st standard to 9 th 
standard 
Kendriya Vidyalaya, Jawahar Lal 
Nehru University, New Delhi, India. 
 
1990–91 Class 10 th (High School)  Kendriya Vidyalaya, Jawahar Lal 
Nehru University, New Delhi, India.  
 
1991– 93 Class 12 th (Intermediate) Goverment Boys Senior Secondary 
School, RK Puram, Sector-II, New 
Delhi, India.  
Subject: Biology, Mathematics, 
Physics, Chemistry and English. 
Final marks: 57 % (PCB) 
UNIVERSITY EDUCATION: 
1993 – 1997 Bachelors in Science (B.Sc.), From Collage of Sri 
Venketeshwara, Delhi University.  
Final marks: 51% 
1997 – 1999 Masters of Science in Biotechnology (M.Sc. in 
Biotechnology), from Banaras Hindu University, Varanasi, 
  116
Uttar Pardesh, India. 
Final marks: 56 % 
 
1998 – 1999 During Masters programmed, I had done one year’s 
complete lab project work on “Hybrid Enzyme: A 
manipulating enzyme design” under the supervision of Dr. 
A.M. Kayastha, Department of Biotechnology, Banaras 
Hindu University, Varanasi, India. 
Aug 2000 – Sept 
2001 
Worked as a Junior Research Fellow under Dr. U.K. Pati 
(Associate Professor), Centre for Biotechnology, Jawaharlal 
Nehru University, New Delhi, India under the project entitled 
“Correlation between Kringle IV and Pentanucleotide repeat 
(PNR) polymorphism in atherosclerosis “funded by Indian 
council of medical research (ICMR) New Delhi, India. 
POSTGRADUATE EDUCATION: 
Oct 2001 – Oct 
2004 
PhD program in the Graduiertenkolleg "Kardiopulmonales 
Gefäßsystem" of the University of Giessen. 
Done Ph.D. thesis work on "Optimization of Microarray 
Technology-Based Expression Profiling for Investigation of 
Different Animal Models of Pulmonary Hypertension" under 
the supervision of PD Dr. Ludger Fink, Institute for 
Pathologie, University Klinikum, Justus Liebig University, 
Giessen - 35392, Germany. 
 
 
Place: Giessen, 2005 
 
         Signature  
 
